CONFIDENTIAL          Protocol BNC210.012              Version 4.0 (US) , 17-Nov-2022 
 
 1 Title Page  
Protocol Title:   
A Phase 2b, Randomized, Double Blind , Two Arm Study to  Investigate  the Effects of BNC210 
Tablet Formulation  Compared to Placebo  in Adults with Post-Traumatic Stress Disorder (PTSD)   
Protocol Number:  BNC210.012  
Amendment Number:  5 
Compound : BNC210  
Brief Title:  A Phase [ADDRESS_826203] -Traumatic 
Stress Disorder (PTSD)  
Study Phase:  2b 
Sponsor Name:  [CONTACT_620806]:  [ADDRESS_826204] , Eastwood , SA, 50 63, AUSTRALIA  
Regulatory Agency Identifier Number(s) : 
Registry  ID 
IND 135,[ADDRESS_826205]  04951076  
 
Approval Date:  17-Nov-[ADDRESS_826206] (IRB). Your acceptance of this document constitutes an agreement that you will not 
disclose the information contained herein to others without the pr ior written consent of Bionomics 
Limited , unless it is necessary to obtain informed consent from potential study participants.  No 
other use or reproduction is authorized by [CONTACT_620775] , nor does Bionomics Limited  
assume any responsibility for unauth orized use of this protocol.  
 
 
 
 
 
CONFIDENTIAL          Protocol BNC210.012              Version 4.0 (US) , 17-Nov-2022 
 
 2  
 
 
Sponsor Signatory:  
 
 
 
 
 
 
 
          [ADDRESS_826207] Information  
 
 
  
  
 
 
  

CONFIDENTIAL          Protocol BNC210.012              Version 4.0 (US) , 17-Nov-2022 
 
 3 Protocol Amendment Summary of Changes Table  
 
DOCUMENT HISTORY  
Document  Date  Rationale for Amendment  
 
   
   
 
  
 
 
   
 
 
 
   
   
 
 
 
   
 
 
 
 
 
   
 
 
 
 
 
 

CONFIDENTIAL          Protocol BNC210.012              Version 4.0 (US) , 17-Nov-2022 
 
 4 Table of Contents  
1. Protocol Summary  ................................ ................................ ................................ .......... 7 
1.1. Synopsis  ................................ ................................ ................................ ............................ 7 
1.2. Schema  ................................ ................................ ................................ ............................ 11 
1.3. Schedule of Activities (SoA)  ................................ ................................ .......................... 12 
2. Introduction  ................................ ................................ ................................ ................... 14 
2.1. Study Rationale  ................................ ................................ ................................ ............... 14 
2.2. Background  ................................ ................................ ................................ ..................... 15 
2.2.1.  Disease Background ................................ ................................ ................................ ........ 15 
  
  
  
  
2.3. Benefit/Risk Assessment  ................................ ................................ ................................ 17 
3. Objectives, Endpoints, and Estimands  ................................ ................................ .......18 
4. Study Design  ................................ ................................ ................................ .................. 21 
4.1. Overall Design  ................................ ................................ ................................ ................ 21 
4.2. Scientific Rationale for Study Design  ................................ ................................ ............ 21 
  
4.4. End of Study Definition  ................................ ................................ ................................ ..22 
5. Study Population  ................................ ................................ ................................ ........... 23 
5.1. Inclusion Criteria  ................................ ................................ ................................ ............ 23 
5.2. Exclusion Criteria  ................................ ................................ ................................ ........... 24 
5.3. Lifestyle Considerations  ................................ ................................ ................................ .27 
5.4. Screen Failures  ................................ ................................ ................................ ................ 27 
5.5. Criteria for Temporarily Delaying Randomization or 
Administration of Study Intervention  ................................ ................................ ............. 27 
6. Study Intervention(s) and Concomitant Therapy  ................................ ..................... 28 
6.1. Study Intervention(s) Administered ................................ ................................ ................ 28 
6.2. Preparation/Handling/St orage/Accountability  ................................ ................................ 29 
6.3. Measures to Minimize Bias: Randomization and Blinding  ................................ ............ 30 
  
  
  
  
6.5. Dose Modification  ................................ ................................ ................................ .......... 32 
6.6. Continued Access to Study Intervention After the End of the 
Study  ................................ ................................ ................................ ............................... 32 
6.7. Treatment of Overdose  ................................ ................................ ................................ ...32 
6.8. Concomitant Therapy  ................................ ................................ ................................ .....32 
6.8.1.  Rescue Medications for Insomnia  ................................ ................................ ................... 33 
7. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal ................................ ................................ ........................ 34 

CONFIDENTIAL          Protocol BNC210.012              Version 4.0 (US) , 17-Nov-2022 
 
 5 7.1. Discontinuation of Study Intervention  ................................ ................................ ............ 34 
7.1.1.  Liver Chemistry Stoppi[INVESTIGATOR_2121]  ................................ ................................ .................. 34 
7.1.2.  QTc Stoppi[INVESTIGATOR_2121]  ................................ ................................ ................................ .....35 
7.1.3.  Suicidal Behavior Stoppi[INVESTIGATOR_2121]  ................................ ................................ ............... 35 
7.1.4.  Temporary Discontinuation  ................................ ................................ ............................ 35 
7.2. Participant Discontinuation/Withdrawal from the Study  ................................ ................ [ADDRESS_826208] to Follow up  ................................ ................................ ................................ ............ 36 
8. Study Assessments and Procedures ................................ ................................ ............. 37 
8.1. Efficacy Assessments  ................................ ................................ ................................ .....38 
8.1.1.  Clinician -Administered PTSD Scale for the DSM -5 (CAPS -5) ................................ .....[ADDRESS_826209] for DSM -5 (PCL -5) ................................ ................................ .............. 39 
8.1.3.  Clinical Global Impression Scales – Severity and Improvement 
(CGI -S/I) ................................ ................................ ................................ ......................... 39 
8.1.4.  Patient Global Impression Scales – Severity and Improvement 
(PGI -S/I) ................................ ................................ ................................ ......................... 39 
8.1.5.  Hamilton Anxiety Rating Scale (HAM -A) ................................ ................................ .....39 
8.1.6.  Montgomery -Åsberg Depression Rating Scale (MADRS) ................................ ............. 39 
8.1.7.  Sheehan Disability Scale (SDS) ................................ ................................ ...................... 39 
8.1.8.  Insomnia Severity Index (ISI)  ................................ ................................ ......................... 39 
8.2. Safety Assessments  ................................ ................................ ................................ ......... 40 
8.2.1.  Physical Examinations  ................................ ................................ ................................ ....40 
8.2.2.  Vital Signs  ................................ ................................ ................................ ....................... 40 
8.2.3.  Electrocardiograms  ................................ ................................ ................................ ......... 40 
8.2.4.  Clinical Safety Laboratory Assessments  ................................ ................................ ........ 41 
8.2.5.  Suicidal Ideation and Behavior Risk Monitoring  ................................ ........................... 41 
8.3. Adverse Events (AEs), Serious Adverse Events (SAEs), and 
Other Safety Reporting  ................................ ................................ ................................ ...42 
8.3.1.  Time Period and Frequency for Collecting AE and SAE 
Information  ................................ ................................ ................................ ..................... 42 
8.3.2.  Method of Detecting AEs and SAEs  ................................ ................................ .............. 43 
8.3.3.  Follow -up of AEs and SAEs  ................................ ................................ ........................... 43 
8.3.4.  Regulatory Reporting Requirements for SAEs  ................................ ............................... 43 
8.3.5.  Pregnancy  ................................ ................................ ................................ ........................ 43 
8.4. Pharmacokinetics  ................................ ................................ ................................ ............ 44 
8.5. Genetics  ................................ ................................ ................................ .......................... 44 
8.6. Biomarkers  ................................ ................................ ................................ ...................... 44 
8.7. Immunogenicity Assessments ................................ ................................ ......................... 44 
8.8. Health Economics OR Medical Resource Utilization and Health 
Economics  ................................ ................................ ................................ ....................... 44 
9. Statistical Considerations  ................................ ................................ ............................. 45 
9.1. Statistical Efficacy Hypotheses  ................................ ................................ ...................... 45 
9.1.1.  Multiplicity Adjustment  ................................ ................................ ................................ ..46 
9.2. Analysis Sets  ................................ ................................ ................................ ................... 47 
9.3. Statistical Analyses  ................................ ................................ ................................ ......... 47 
9.3.1.  General Considerations  ................................ ................................ ................................ ...47 
CONFIDENTIAL          Protocol BNC210.012              Version 4.0 (US) , 17-Nov-2022 
 
 6 9.3.3.  Primary and Key Secondary Endpoint/Estimand Analyses  ................................ ............ 48 
9.3.4.  Supportive Analyses for Primary and Key Secondary Efficacy 
Endpoints  ................................ ................................ ................................ ........................ 49 
9.3.5.  Multiple Imputation Methods  ................................ ................................ ......................... 49 
9.3.6.  Other Secondary Endpoints Analyses  ................................ ................................ ............. 50 
9.3.7.  Safety Analyses  ................................ ................................ ................................ ............... 50 
  
9.4. Population Pharmacokinetic (PK) Analysis  ................................ ................................ ...50 
9.5. Interim Analysis  ................................ ................................ ................................ .............. 50 
9.6. Sample Size Determination  ................................ ................................ ............................ 50 
10. Supporting Documentation and Operational Considerations  ................................ ..52 
10.1.  Appendix 1: Regulatory, Ethical, and Study Oversight 
Considerations  ................................ ................................ ................................ ................ 52 
10.1.1.  Regulatory and Ethical Considerations  ................................ ................................ ........... 52 
10.1.2.  Financial Disclosure ................................ ................................ ................................ ........ 52 
10.1.3.  Informed Consent Process  ................................ ................................ .............................. 53 
10.1.4.  Data Protection ................................ ................................ ................................ ................ 53 
10.1.5.  Independent Safety Review  ................................ ................................ ............................ 54 
10.1.6.  Data Quality Assurance  ................................ ................................ ................................ ..54 
10.1.7.  Source Documents  ................................ ................................ ................................ .......... 55 
10.1.8.  Study and Site Closure  ................................ ................................ ................................ ....55 
10.1.9.  Publication Policy  ................................ ................................ ................................ ........... 56 
10.2.  Appendix 2: Clinical Laboratory Tests  ................................ ................................ ........... 57 
10.3.  Appendix 3: AEs and SAEs: Definitions and Procedures for 
Recording, Evaluating, Follow -up, and Reporting  ................................ ......................... 59 
10.3.1.  Definition of AE  ................................ ................................ ................................ ............. 59 
10.3.2.  Definition of SAE  ................................ ................................ ................................ ........... 60 
10.3.3.  Recording and Follow -Up of AE and/or SAE  ................................ ................................ 61 
10.3.4.  Reporting of SAEs  ................................ ................................ ................................ .......... 64 
10.4.  Appendix 4: Contraceptive and Barrier Guidance  ................................ .......................... 66 
10.4.1.  Definitions ................................ ................................ ................................ ....................... 66 
10.4.2.  Contraception Guidance ................................ ................................ ................................ ..67 
10.5.  Appendix 5: Liver Safety: Sugg ested Actions and Follow -up 
Assessments  ................................ ................................ ................................ .................... 68 
10.6.  Appendix 6: Abbreviations  ................................ ................................ ............................. 71 
11. References  ................................ ................................ ................................ ...................... 74 

CONFIDENTIAL          Protocol BNC210.012              Version 4.0 (US) , 17-Nov-2022 
 
 7 1.  Protocol Summary  
1.1. Synopsis  
Protocol Title:  A Phase 2b, Randomized, Double Blind, Two Arm Study to Investigate the 
Effects of BNC210 Tablet Formulation Compared to Placebo in Adults with 
Post-Traumatic Stress Disorder (PTSD)   
Brief  Title:  A Phase [ADDRESS_826210] -
Traumatic Stress Disorder (PTSD)  
Rationale : 
This Phase 2b study will assess the potential effect of BNC210 in the treatment of P ost-
Traumatic Stress Disorder (PT SD), a condition which is classified in the Diagnostic and 
Statistical Manual of Mental Disorders, Fifth Edition (DSM -5) as a Trauma and Stressor -Related 
Disorder.  
Previous human studies with BNC210 have established its safety and tolerability and 
demonst rated effects in a panic model in healthy volunteers. In a Phase 2a study in generalized 
anxiety disorder (GAD) patients (BNC210.006) using functional magnetic resonance imaging 
(fMRI), BNC210 reduced bilateral amygdala reactivity to fearful faces in an Em otional Faces 
Task and connectivity between the left amygdala and anterior cingulate cortex (ACC). In both 
anxiety and PTSD patients, significant arousal of the amygdala occurs in response to viewing 
fearful faces. Reduction of this response has been demon strated by [CONTACT_620776]. In addition, anxious patients have a strong connection between the ACC and the 
amygdala. The reduction of connectivity in this circuit, and of amygdala hyperactivity, 
demonstrate BNC210 efficacy on two valida ted biomarkers of anxiety -induced brain changes. In 
the same study, BNC210 caused a significant reduction in defensive behavior (threat avoidance), 
demonstrating the positive effect of BNC210 on modulating hypothalamic pi[INVESTIGATOR_620757]. Thes e human data demonstrate proof -of-biology for BNC210 and potential for efficacy 
in the treatment of anxiety disorders and PTSD.  
Furthermore, based on preclinical data demonstrating BNC210’s positive effects on fear 
extinction, BNC210 is being studied in PT SD patients where deficits in fear extinction are 
thought to contribute to the pathology of this disorder.   
BNC210 has previously been evaluated in patients with PTSD in a randomized, double -blind, 
placebo -controlled trial over 12 weeks (BNC210.007). BNC2 10 was administered orally as a 
suspension and was well tolerated with no pattern of drug -related adverse effects becoming 
apparent. However, improvements in the efficacy measurement of Clinician -Administered PTSD 
Scale for the DSM -5 (CAPS -5) Total Symptom  Severity scores were not statistically different 
between BNC210 and placebo. Using population pharmacokinetics, exposure to BNC210 was 
modelled in the trial participants  and was substantially less than that expected when compared to 
pharmacokinetic ( PK) data from a healthy volunteer study with the same suspension formulation 
(BNC210.005). This may be attributed in part to the unsuitability of the suspension formulation 
for an out -patient study, in particular, its dependence on food fo r optimal absorption.  A 
pharmacometric exposure -response relationship was modelled based on the population PK and 
CONFIDENTIAL          Protocol BNC210.012              Version 4.0 (US) , 17-Nov-2022 
 
 9 • To assess the effects of BNC210 on 
Investigator -rated symptoms of 
anxiety and depression in participants 
with PTSD  
• To assess the effects of BNC210 on 
patient -reported symptoms of PTSD   
• To assess the effects of BNC210 on 
patient -reported global functioning  
and sleep quality in participants with 
PTSD  
• To assess the safety and tolerability of 
BNC210 in participants with PTSD  • Proportion of participants who achieve 
remission in PTSD symptoms with a 
score of <11 on CAPS -5 Total 
Symptom Severity Scores  
• The difference between B NC210 and 
placebo in endpoint  scores  (Week 12) 
in Clinical Global Impression – 
Improvement Scale (CGI -I) 
• The difference between BNC210 and 
placebo in change from Baseline to 
endpoint (Week 12) in  Hamilton 
Anxiety Rating Scale (HAM -A) 
• The difference between B NC210 and 
placebo in change from Baseline to 
endpoint (Week 12) in  Montgomery -
Åsberg Depression Rating Scale 
(MADRS)  
• The difference between B NC210 and 
placebo in change from Baseline to 
endpoint (Week 12) in  PTSD 
Checklist for DSM -5 (PCL -5) 
• The difference between B NC210 and 
placebo in change from Baseline to 
endpoint (Week 12) in  Patient Global 
Impression – Severity and 
Improvement Scales (PGI -S/I) 
• The difference between B NC210 and 
placebo in change from Baseline to 
endpoint (Week 12) in  Insomnia 
Severity Index (ISI)  
• The following assessments will be 
used to monitor safety and tolerability 
from Baseline t o Week 15:  vital signs, 
electrocardiogram (ECG), hematology 
and blood chemistry, urinalysis, 
physical examination, and Columbia 
Suicide Severity Rating Scale (C -
SSRS). Reporting of continuous 
Adverse E vents (AE).  
 
 
CONFIDENTIAL          Protocol BNC210.012              Version 4.0 (US) , 17-Nov-2022 
 
 10 Overall Design : 
This is a randomized, double -blind, placebo -controlled, parallel group, multi -center study with a 
12 week, 2 -arm treatment period .  Participants will attend  a Screening visit within 3 weeks 
before randomization to confirm eligibility. Approximately 200 participants who fulfill the 
inclusion criteria and none of the exclusion criteria will be randomized using a 1:1 ratio to 
receive either BNC210 900 mg twice d aily (b.i.d.) or matched placebo. Participants will then 
complete 12 weeks of treatment with their allocated study intervention.   Participants will  
complete study visits every 2 weeks during the treatment period and  a Follow -up visit at Week 
15 (i.e., [ADDRESS_826211] study intervention is administered). In the event that a participant 
cannot be physically present at the study site for a specified visit due to coronavirus disease 2019 
(COVID -19) related restrictions, quarantine  or positive test, or  a natural disaster, a 
telehealth/remote visit may be completed instead if appropriate.  
Brief Summary : 
The purpose of this study is t o assess the effects of BNC210  compared to placebo  on PTSD  s
ymptom severity as  measured by [CONTACT_88853] -5 Total Symptom Severity Scores .  
Number of Participant s: 
Approximately 400 participants will be screened to achieve a total enrollment of approximately 
200 randomly assigned  participants . 
Intervention Groups  and Duration : 
The total duration for each participant enrolled in the study is expected to be up to 18 weeks  
following the sequence below:  
• Screening period: Up to 3 weeks  
• Treatment period : 12 weeks  
• Follow up visit: [ADDRESS_826212] study intervention  is administered  
The visit frequency during the treatment period  will be every 2 weeks .  Details of study 
assessments to be conducted at each visit are included in the Schedule of Activities (SoA).  
Each participant will be randomized in a 1:1 ratio to receive b.i.d. doses of BNC210 900 mg OR 
placebo over the 12 -week treatment period.  Treatment assign ments will be double -blinded.   
Dose adjustments are not permitted during the study . Dose interruptions are only allowed for 
safety purposes in line with Section 7.1.4  of the study protocol.   Discontinuation of study 
intervention for safety purposes is described in Section 7.1.  
 
 
 
 
 
 
CONFIDENTIAL          Protocol BNC210.012              Version 4.0 (US) , 17-Nov-2022 
 
 11 Data Monitoring /Other  Committee:   
An independent Safety Re view Committee will be established to monitor participant  safety 
throughout the study. The meetings will occur approximately every 3 months and will review all 
safety data including vital signs, ECG, pathology results, physical examinations, C -SSRS and 
continuous AE reporting.  
 
1.2. Schema  
Section not applicable.  
 
CONFIDENTIAL  Protocol BNC210.012                                          Version 4.0 (US) , 17-Nov-2022 
 
  12 1.3. Schedule of Activities  (SoA)  
 
Assessment1 Screening  
<-21 days  Treatment Period  
Week 15 / 
Follow -up 
(+5 days)  Baseline2 
(+3 days)  Week 23 
(+3 days)  Week 4  
(+3 days)  Week 6  
(+3 days)  Week 8  
(+3 days)  Week 10  
(+3 days)  Week 12 / Early 
Termination  
(+3 days)  
Informed consent  X         
Inclusion and exclusion criteria4 X         
Demography  X         
Medical history including current & prior medications  X         
Structured Clinical Interview for DSM -5 disorders – Clinical 
Trials Version (SCID -5-CT) and Personality Disorders (SCID -
5-PD) Borderline Personality Disorder section only X   
  
  
  
Human immunodeficiency virus (HIV), Hepatitis B surface 
antigen (HBsAg) and Hepatitis C virus (HCV) antibody screen  X         
Serum pregnancy test (if applicable)  X         
Urine pregnancy test (if applicable)   X      X  
Urine drug screen5 X X  X  X  X  
12-lead electrocardiogram (ECG)6  X   X  X  X  
Vital signs7  X X  X  X  X X 
Physical examination (including height only at Screening; 
weight only at Screening and Week 12 / Early Termination)8 X X  X  X  X X 
Clinical labs (hematology, biochemistry, urinalysis)  X X  X X9 X X9 X X 
 
1 See Section 8 for guidance on the order of assessments to be completed at each visit  
2 All baseline assessments to be completed pre -dose 
3 Visit can be performed at the study site, or remotely via phone/video call  
[ADDRESS_826213] 5 minutes prior to performing 
the ECG.  The same ECG machine should be used for all recordings from an individual participant, where possible.  Single trip licate repeat d uring Screening allowed in the event of a clinically 
significant abnormality including prolonged Fridericia corrected QT interval (QTcF).  
7 Blood pressure and heart rate will be measured in a sitting position after resting for 5 minutes  
8 Full physical exa mination at Screening & W12 / Early Termination. Abbreviated physical examination at Baseline, Week 4, Week 8, and Follow -up 
9 Blood biochemistry testing only for Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Alkaline Phosphatase (A LP), Bilirubin (direct and total)  
CONFIDENTIAL  Protocol BNC210.012                                          Version 4.0 (US) , 17-Nov-2022 
 
  13 Assessment1 Screening  
<-21 days  Treatment Period  
Week 15 / 
Follow -up 
(+5 days)  Baseline2 
(+3 days)  Week 23 
(+3 days)  Week 4  
(+3 days)  Week 6  
(+3 days)  Week 8  
(+3 days)  Week 10  
(+3 days)  Week 12 / Early 
Termination  
(+3 days)  
Columbia Suicide Severity Rating Scale (C -SSRS)[ADDRESS_826214] for DSM -5 (LEC -5)11 X         
Clinician -Administered PTSD Scale for DSM -5 (CAPS -5)12 X X  X  X  X  
Montgomery -Åsberg Depression Rating Scale (MADRS)  X X  X  X  X  
Randomization13  X        
Hamilton Anxiety Rating Scale (HAM -A)  X  X  X  X  
Clinical Global Impressions Severity and Improvement scales 
(CGI -S/I)14  X  X  X  X  
Patient Global Impression – Severity and Improvement scales 
(PGI -S/I)[ADDRESS_826215] (PCL -5)  X      X  
Sheehan Disability Scale (SDS)   X  X  X  X  
Insomnia Severity Index (ISI)   X  X  X  X  
Study Intervention dispensing   X15  X  X    
Concomitant medications recording   X X X  X  X X 
Adverse Event (AE) recording16   X X  X  X X 
Blood sample collection for concentration of BNC210     X  X  X  
 
10 “Screening C -SSRS” to be used at Screening. “C -SSRS Since Last Visit” to be used at every other visit  
[ADDRESS_826216] month version to be used at every visit and should be aud io recorded at every visit using the provided iPhone.  
13 Once eligibility has been confirmed   
14 Improvement scale at Week 12 only  
15 Participants to administer one PM dose on day of completing Baseline assessments and randomization  
16 See Appendix 3 for defi nitions  
 
 
CONFIDENTIAL    Protocol BNC210.012              Version 4.0 (US) , 17-Nov-2022 
 
 14 2. Introduction  
Bionomics Limited is devel opi[INVESTIGATOR_620758]210  for the treatment of anxiety, and trauma - and stressor -
related, disorders.  BNC210 is a negative allosteric modulator of the alpha -7 nicotinic 
acetylcholine receptor (alpha -7 nAChR), which represents a novel target for the treatment of 
these d isorders.  BNC210 is a new chemical entity which has exhibited potent anxiolytic activity 
in a range of animal models at low doses with a wide therapeutic window.  There is an absence 
of the adverse effects particularly associated with standard -of-care tre atments for acute disorders, 
such as benzodiazepi[INVESTIGATOR_1651], and the antidepressants used in first line therapy for chronic disorders.  
2.1. Study Rationale  
This Phase 2b study will assess the potential effect of BNC210 in the treatment of PTSD, a 
condition which is classified in the Diagnostic and Statistical Manual of Mental Disorders, Fifth 
Edition ( DSM -5) as a Trauma and Stressor -Related Disorder.  
Previous human studies with BNC210 have established its safety and tolerability and 
demonstrated effects in a panic model in healthy volunteers. In a Phase 2a study in generalized 
anxiety disorder (GAD) pa tients (BNC210.006)  using functional magnetic resonance imaging 
(fMRI) , BNC210 reduced bilateral amygdala reactivity to fearful faces in an Emotional Faces 
Task and connectivity between the left amygdala and anterior cingulate cortex (ACC). In both 
anxiety  and PTSD patients , significant arousal of the amygdala occurs in response to viewing 
fearful faces. Reduction of this response has been demonstrated by [CONTACT_620776]. In addition, anxious patients  have a strong connection between the  ACC and the 
amygdala.  The reduction of connectivity in this circuit, and of amygdala hyperactivity, 
demonstrate BNC210 efficacy on two validated biomarkers of anxiety -induced brain changes. In 
the same study, BNC210 caused a significant reduction in defen sive behavior (threat avoidance), 
demonstrating the positive effect of BNC210 on modulating hypothalamic pi[INVESTIGATOR_620757]. These human data demonstrate proof -of-biology for BNC210 and potential for efficacy 
in the treatment of anxiety disord ers and PTSD.  
Furthermore, based on preclinical data demonstrating BNC210’s positive effects on fear 
extinction, BNC210 is being studied in PTSD patients where deficits in fear extinction are 
thought to contribute to the pathology of this disorder.   
BNC21 0 has previously been evaluated in patients with PTSD in a randomized, double -blind, 
placebo -controlled trial over 12 weeks (BNC210.007). BNC210 was administered orally as a 
suspension and was well tolerated with no pattern of drug -related adverse effects becoming 
apparent. However, improvements in the efficacy measurement of Clinician -Administered PTSD 
Scale for the DSM -5 (CAPS -5) Total Symptom Severity scores were not statistically different 
between BNC210 and placebo. Using population pharmacokinetics, e xposure to BNC210 was 
modelled in the trial participants  and was substantially less than that expected when compared to 
pharmacokinetic ( PK) data from a healthy volunteer study with the same suspension formulation 
(BNC210.005). This may be attributed in pa rt to the unsuitability of the suspension formulation 
for an out -patient study, in particular, its dependence on food for optimal absorption.  A 
pharmacometric exposure -response relationship was modelled based on the population PK and 
CONFIDENTIAL    Protocol BNC210.012              Version 4.0 (US) , 17-Nov-[ADDRESS_826217] clinical efficacy in 
PTSD provided that adequate plasma exposures are achieved.   
A spray -dried dispersion tablet formulation of BNC210 has since been developed and when 
evaluated in single and multiple  dose PK studies in healthy adult volunteers has demonstrated 
that it can safely and reliably achieve the exposure predicted by [CONTACT_620777], without the dependence on food, and hence justifies 
furth er evaluation of BNC210 as a potential treatment for adults with PTSD.  
2.2. Background  
2.2.1.  Disease Background  
PTSD may result from exposure to a traumatic event during which an individual experienced, 
witnessed, or was confronted with the actual threat of death or serious injury, or the threat to 
physical integrity to self or others. PTSD symptoms can be divided into four clusters: (1) 
persistent re -experiencing of the trauma, (2) avoidance behavior associated with feelings of 
detachment and emotional numbness, (3) negative alterations in cognitions and mood, and ( 4) 
symptoms of increased autonomic arousal . 
The lifetime pre valence of PTSD in the general population is approximately 8% making PTSD 
the fifth most prevalent mental disorder in the [LOCATION_002] ( Krystal et al., 2017 ). People with 
PTSD continue to exp erience adverse effects of their exposure to trauma for years afterwards, 
when the trauma is no longer present, and this inability to return to the pre -trauma state 
differentiates PTSD from other stressor -related disorders.  
Treatment is based on early int erventions, psychotherap y and pharmacotherapy. Only two 
pharmacological agents, the antidepressants Paxil® (paroxetine) and Zoloft® (sertraline), 
belonging to the selective serotonin reuptake inhibitors class (SSRIs), are Food and Drug 
Administration ( FDA )-approved for the treatment of PTSD, but they have not been shown to 
ameliorate the full range of PTSD symptoms, and complete remission of symptoms is rare. It has 
been estimated that no more than 20 to  30% of people with PTSD are effectively treated, and a 
high percentage of those who begin  PTSD treatment eventually drop out ( Alexander, 2012 ; 
VA/DOD Clinical Practice Guideline for the Management of Posttraumatic Stress Disorder and 
Acute Stress Disorder, 2017 ). The use of b enzodiazepi[INVESTIGATOR_050] s are contrai ndicated for PTSD  based on 
their unproven  efficacy and their risks for abuse  and dependence in a population at risk of co-
morbid substance use disorder.  
There is a need for improved therapeutics for PTSD with greater clinical benefit, fewer side  
effects and a faster onset of action, something that might be achieved by [CONTACT_24096] a different  
mechanism of action.  
  
 
 
 
 
 

CONFIDENTIAL    Protocol BNC210.012              Version 4.0 (US) , 17-Nov-2022 
 
 16  
 
  
   
 
 
 
 
 
  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
  
 
 
 
 
 
 
 

CONFIDENTIAL    Protocol BNC210.012              Version 4.0 (US) , 17-Nov-2022 
 
 19 • To assess the effects of BNC210 on 
patient -reported symptoms of PTSD   
• To assess the effects of BNC210 on 
patient -reported global functioning  
and sleep quality in participants  with 
PTSD  
• To assess the safety and tolerability of 
BNC210 in participants  with PTSD  • The difference between B NC210 and 
placebo in endpoint scores (Week 12) 
in Clinical Global Impression – 
Improvement Scale (CGI -I) 
• The difference between BNC210 and 
placebo in change from Baseline to 
endpoint (Week 12) in  Hamilton 
Anxiety Rating Scale (HAM -A) 
• The difference between B NC210 and 
placebo in change from Baseline to 
endpoint (Week 12) in  Montgomery -
Åsberg Depression Rating Scale 
(MADRS)  
• The difference between B NC210 and 
placebo in change from Baseline to 
endpoint (Week 12) in  PTSD 
Checklist for DSM -5 (PCL -5) 
• The difference between B NC210 and 
placebo in change from Baseline to 
endpoint (We ek 12) in  Patient Global 
Impression – Severity and 
Improvement Scales (PGI -S/I) 
• The difference between B NC210 and 
placebo in change from Baseline to 
endpoint (Week 12) in  Insomnia 
Severity Index (ISI)  
• The following assessments will be 
used to monitor safety and tolerability  
from Baseline t o Week 15 : vital signs, 
electrocardiogram (ECG), hematology 
and blood chemistry, urinalysis, 
physical examination, and Columbia 
Suicide Severity Rating Scale (C -
SSRS). Reporting of continuous 
Adverse Events (A E). 
 
 
 
 
 
CONFIDENTIAL    Protocol BNC210.012              Version 4.0 (US) , 17-Nov-2022 
 
 21 4. Study Design  
4.1. Overall Design  
This is a randomized, double -blind, placebo -controlled, parallel group, multi -center study with a 1
2 week, 2 -arm treatment period .  Participants will attend a Screening visit within 3 weeks before 
randomization to confirm eligibility. Approximately 200 participants who fulfill the inclusion 
criteria and none of the exclusion c riteria will be randomized using a 1:1 ratio to receive either 
BNC210 900 mg b.i.d. or matched placebo. Participants will then complete 12 weeks of 
treatment with their allocated study intervention.  Participants will complete study visit s every  2 
weeks during the treatment period and a Follow -up visit at Week 15 (i.e., [ADDRESS_826218] 
study intervention is administered). In the event that a participant cannot be physically present at 
the study site for a specified visit due to coronavirus disease 2019 ( COVID -19) related 
restrictions, quarantine or positive test, or a natural disaster, a telehealth/remote visit may be 
completed instead if appropriate (see Section 8).  
Details are included in the Schedule of Activities  (SoA).  
4.2. Scientific Rationale for Study Design  
This study evaluates as its primary endpoint, the effects of BNC210 compared to placebo on 
PTSD symptom severity using the  CAPS -5. CAPS -5 is the universally accepted scale fo r 
diagnosis of PTSD as well as for assessment of PTSD symptom severity. It can monitor 
worsening or improvement in a participant’s symptoms by [CONTACT_2931] a well -defined scoring 
system according to specific criteria. It is therefore an appropriate tool for me asuring the primary 
endpoint of this study  and clinically meaningful changes in PTSD symptom severity .  
The primary and secondary endpoints in this study will utilize clinician -administered scales as 
well as patien t-reported  scales.   A double blind, placeb o-controlled study design has been chosen 
as a well-established and appropriate study design to minimize the potential for bias in study 
assessments or in reporting of AEs . Clinic staff and participants are blinded to treatment 
assignments to ensure object ive reporting.   In addition, participants will be randomized 1:1 to 
receive either BNC210 or placebo to ensure there are no order effects and to further minimize 
bias. 
  
 
 
 
 
 
 
 
 
 
 
 

CONFIDENTIAL    Protocol BNC210.012              Version 4.0 (US) , 17-Nov-[ADDRESS_826219] participant in the study .  
 

CONFIDENTIAL    Protocol BNC210.012              Version 4.0 (US) , 17-Nov-[ADDRESS_826220] the study eligibility 
criteria during the Screening period.  At the initial Screening visit, each participant  will 
participate in the informed consent process and sign and date th e ICF before any procedures 
specified in this protocol are performed.  
Prospective approval of protocol deviations to recruitment and enrollment criteria, also known as 
protocol waivers or exemptions, is not permitted.  
5.1. Inclusion Criteria  
Particip ants are eligible to be included in the study only if all of the following criteria apply:  
Age 
1. Participant must be 18 to 75 years of age inclusive, at the time of signing informed 
consent  
Type of Participant and Disease Characteristics  
2. Current diagnosis  of PTSD  as defined by [CONTACT_25905] -5, with a CAPS -5 Total Symptom S
everity Score of >30 at Screening and Baseline  and no >25% decrease in Score from 
Screening to Baseline  
3. The index trauma event must have occurred in adulthood, i.e., when the participant was 
≥18 years of age  
4. In the opi[INVESTIGATOR_620759] a high probability for adherence 
with and c ompletion of the study  
5. Ability to swallow tablets  
6. Fluent in English and able to understand and comply with written and verbal protocol -
related requirements  
Sex and Contraceptive/Barrier Requirements   
7. Contraceptive use by [CONTACT_620778].  
a. Male participants are eligible to participate if they agree to the following during the 
study intervention period and for at least [ADDRESS_826221] dose of study 
intervention : 
• Refrain from donating sperm  PLUS, either:  
o Be abstinent from heterosexual  interc ourse as their preferred and usual 
lifestyle (abstinent on a long term and persistent basis) and agree to remain 
abstinent  
OR 
o Must agree to use a male condom  with female partner us ing an additional 
highly effective contraceptive method with a failure rate of <  1% per year as 
described in Appendix 4 Contraceptive and Barrier Requirements , when 
CONFIDENTIAL    Protocol BNC210.012              Version 4.0 (US) , 17-Nov-2022 
 
 24 having sexual intercourse with a woman of childbearing potential (WOCBP) 
who is not currently pregnant  
b. Female participants are eligible to participate i f they are not pregnant or 
breastfeeding and the following conditions applies:  
o Is a woman of nonchildbearing potential (WONCBP) as defined in Appendix  4 
Contraception and Barrier Guidance.   
OR 
o Is a WOCBP and using a contraceptive method that is highly effective (with a 
failure rate of <  1% per year), preferably  with low user dependency, as 
described in Appendix  [ADDRESS_826222] dose of study 
intervention  and agrees not to donate eggs (ova, oocytes) for the purpose of  
reproduction during this period.  The Investigator should evaluate the potential 
for contraceptive method failure ( e.g., noncompliance, recently initiated) in 
relationship to the first dose of study intervention.  
• A WOCBP must have a negative serum  pregnanc y test  at Screening and a 
negative urine test at Baseline ( within [ADDRESS_826223] dose of study 
intervention ). 
The Investigator is responsible for review of medical history, menstrual history, 
and recent sexual activity to decrease the risk for inclusion of a woman with an 
early undetected pregnancy.  
Informed Consent  
8. Capable of giving signed informed consent as described in Appendix 1 which includes 
compliance with the requirements and restrictions listed in the ICF and in this protocol.  
5.2. Exclusion Criteria  
Participants are excluded from the study if any of the following criteria apply:  
Medical Conditions  
1. A period of less than 6 months since the index trauma event  occurred  
2. Current and ongoing exposure to the trauma that caused the PTSD  
3. Complex PTSD, defined as a condition that may develop following exposure to an 
event or series of events of an extreme and prolonged or repetitive nature, which the 
participant experienced as extremely threatening or  horrific and from which escape was 
difficult or impossible (e.g., torture, slavery, genocide campaigns, prolonged domestic 
violence, repeated childhood sexual or physical abuse). If affect dysregulation and 
interpersonal dysfunction are primary over other core PTSD symptoms, in the 
Investigator ’s opi[INVESTIGATOR_1649], participants  should be excluded .  
4. Severe depression as measured by a score of ≥ 35 on the Montgomery -Åsberg 
Depression Rating Scale (MADRS) at Screening  
CONFIDENTIAL    Protocol BNC210.012              Version 4.0 (US) , 17-Nov-2022 
 
 25 5. Bipolar, Borderline Personality and other psychotic disorders as identified at Screening 
using the Structured Clinical Interview for DSM -5 Disorders – Clinical Trials Version 
(SCID -5-CT) and Personality Disorders (SCID -5-PD). 
6. History of moderate to severe traumatic brain injury  
7. History of seizure disorders, uncontrolled sleep apnoea or severe ne urologic disease  
8. Any moderate o r severe substance use disorder according to DSM -5 in the 12 months 
prior to Screening  
9. Increased risk of suicide, defined as:  
• Any suicide attempt in the 12 months prior to Screening disclosed by [CONTACT_620779] (C -SSRS)  
• Any suicidal ideation with intent (yes to item 4 and/or 5) or suicidal behavior in the 
past 12 months, as captured at Screening using the C -SSRS  
• A score > 4 on item 10 of the MADRS at Screening.  
10. History or presence of impaired renal function, as indicated by [CONTACT_620780], blood urea nitrogen (BUN) or plasma urea, or moderate to severe 
renal dysfunction as defined by [CONTACT_16424] -Gault equation (estimated glomerular 
filtration r ate (eGFR) <50 mL/min)  
11. Alanine transaminase (ALT), aspartate transaminase (AST) or alkaline phosphatase 
(ALP) > 2.0 x upper limit of normal (ULN)  
12. Total bilirubin > 1.[ADDRESS_826224] (isolated bilirubin > 1.[ADDRESS_826225] bilirubin < 35%)  
13. Current or chronic history of liver disease. This includes but is not limited to hepatitis 
virus infections, drug - or alcohol -related liver disease, nonalcoholic steatohepatitis, 
autoimmune hepatitis, hemochromatosis, Wilson’s di sease,  α-[ADDRESS_826226] results (biochemist ry, 
hematology or urinalysis) as assessed by [CONTACT_737]  
15. Blood Pressure systolic >160 mmHg or diastolic >90 mmHg. Two repeat measures are 
allowed at the discretion of the Investigator  
16. Fridericia -corrected QT interval (QTcF) >450 msec for males and QTc F >470 msec for 
females, or QTc >480 msec in participants with bundle branch block, as measured by 
[CONTACT_620781]  
17. Any clinically significant ECG abnormality as determined by [CONTACT_620782]  
18. A family history of congenital long QT syndrome, Brugada syndrome or unexplained 
sudden cardiac death  
 
CONFIDENTIAL    Protocol BNC210.012              Version 4.0 (US) , 17-Nov-2022 
 
 26  Prior/Concomitant Therapy  
19. The use of antidepressant medications within 30 days (fluoxetine within 90 days)  of 
Screening.  The use of alprazolam, flunitrazepam and chronic daily use of other 
benzodiazepi[INVESTIGATOR_373377] 90 day s of Screening. The use of other psychotropic  active 
medications within 5 days of Screening.  
20. Failed more than three trials of antidepressant me dication(s) prescribed for the 
treatment of PTSD. Each trial must have lasted at least [ADDRESS_826227] for a minimum of three months  prior to Screening.  
22. The use of cytochrome P450 3A4 inducers within 30 days of Screening  
23. The use of moderate -strong cytochrome P450 3A4 inhibitors within 2 weeks of 
Screening.  This includes but is not limited to, grapefruit or grapefruit -containing 
produc ts. 
Prior/Concurrent Clinical Study Experience  
24. Current enrolment OR past participation in another investigational study in which an 
investigational intervention (e.g., drug, vaccine, invasive device) was administered 
within 30 days before signing of consent  in this clinical study.  
25. Previously participated in Bionomics’ Phase 2 PTSD study BNC210.007 (RESTORE 
study)  
Diagnostic Assessments  
26. Positive result for human immunodeficiency virus (HIV), hepatitis B surface antigen 
(HBsAg), or hepatitis C (HCV) at Scree ning  
27. Positive urine test for an illicit substance, excluding cannabis, at Screening or Baseline  
Other Exclusions  
28. History of allergies, allergic reactions or hypersensitivity to BNC210 or excipi[INVESTIGATOR_840]  
29. A member of the U nited States military currently servin g on active duty  
30. In the process of litigating for compensation for a psychiatric disorder. Participants  
who are in the process of applying for medical or V eterans Affairs  benefits and/or 
those who have settled a disability claim prior to enrollment in the trial are eligible.  
31. Participants that, in the opi[INVESTIGATOR_689], are not suitable to participate in the 
study due to clinically significant findings from medical history that could interfere 
with the objectives of the study or put the participant  at risk or any othe r reason the 
Investigator deems applicable  
 
 
CONFIDENTIAL    Protocol BNC210.012              Version 4.0 (US) , 17-Nov-2022 
 
 27 5.3. Lifestyle Considerations  
There are no specific lifestyle considerations or restrictions applicable to this study outside of the 
criteria detailed in Sections 5.1, 5.2 and 6.8.  However, over the course of the study, participants  
should  be counseled on the importance of maintaining  consistent behaviors. This includes 
limiting any change to alcohol , cannabis  or tobacco use, dietary intake, and sleep patterns when 
compared to Baseline. Participants  will also be encouraged to attend study visits at the same time 
of day to avoid possibl e diurnal variation in measurement responses.   
5.4. Screen Failures  
Participants who sign and date the ICF but who fail to meet the inclusion and exclusion criteria 
are considered screen failures. Reason(s) for screen failure must be documented by [CONTACT_620783] a timely fashion.  
A minimal set of screen failure information is required to ensure transparent reporting of screen 
failure participants to meet the Consolidated Standards of Reporting Trials (CONSORT) 
publishing requirements and to respond to queries from regulatory authorities. Min imal 
information includes demography, screen failure details, eligibility criteria, and any SAE s. 
In the event that a participant  fails a clinical l aboratory or ECG screening assessment, that 
assessment can be repeated once only  during the screening period . The repeat assessment must 
be completed within the allowed screening period (21 days + 3 days of Baseline)  for eligibility 
purposes. If the repeat  assessment cannot be completed within the screening period, the 
participant  must be re -screened in entirety. Participants  who fail any other screening assessment 
must be screen -failed.   
Individuals who do not meet the criteria for participation in this st udy (screen failure) may be 
rescreened, if deemed appropriate by [CONTACT_620784]/Medical Monitor. However, individuals who do not meet the criterion for CAPS -5 Total 
Symptom Severity Score in line with inclusion criterion #2,  will not be eligible for rescreening. 
Rescreened participants should be reconsented and assigned a new participant number (Subject 
ID) for every screening/rescreening event.  
5.5. Criteria for Temporarily Delaying Randomization or Adminis tration 
of Study Intervention  
Section not applicable  
 
CONFIDENTIAL    Protocol BNC210.012              Version 4.0 (US) , 17-Nov-2022 
 
 28 6. Study Intervention (s) and Concomitant Therapy  
Study intervention is defined as an y investigational intervention (s), marketed product(s), 
placebo , or medical device (s) intended to be administered to a study participant according to the 
study protocol.  
Detailed information related to the composition of the study interventions to be used in this study 
can be found in the study Investigational Product  Manual  and the Investigator’s Brochure . 
Participants will administer study intervention b.i.d.  for 12 weeks.  
 
 
 
 
 
6.1. Study Intervention(s) Administered  
 
Table 1.  Study Intervention(s) Administered  
Intervention Label  BNC210 900 mg  Placebo  
Intervention Name  [CONTACT_620807]210  Placebo  
Intervention Description  BNC210 900 mg b.i.d . for 12 
weeks  Placebo b.i.d.  for 12 weeks  
Type  Drug Drug 
Dose Formulation  Tablet  Tablet 
Unit Dose Strength  225 mg  N/A 
   
Route of Administration  Oral Oral 
Use Experimental  Placebo  Comparator   
Investigational Medicinal 
Product (IMP)  IMP IMP 
Sourcing  Provided centrally by [CONTACT_620785]210.012              Version 4.0 (US) , 17-Nov-2022 
 
 29 Packaging and Labeling  4  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.  Study Arm(s)  
 
6.2. Preparation/Handling/Storage/Accountability  
1. The Investigator or designee must confirm appropriate temperature conditions have been 
maintain ed during transit for all study intervention received , and any discrepancies are 
reported and resolved before use of the study intervention.  
2. Only participants enrolled in the study may receive study intervention, and only 
authorized site staff may supply o r administer study intervention. All study intervention 
must be stored in a secure, environmentally controlled, and monitored (manual or 
automated) area in accordance with the labeled storage conditions with access limited to 
the investigator and authorize d site staff.  
3. The Investigator, institution, or the head of the medical institution (where applicable) is 
responsible for study intervention accountability, reconciliation, and record maintenance 
(i.e., receipt, reconciliation, and final disposition record s). Arm Title  BNC210  Placebo  
Arm Type  Experimental  Placebo  Comparator  
Associated Intervention Labels  BNC210 900  mg Placebo  

CONFIDENTIAL    Protocol BNC210.012              Version 4.0 (US) , 17-Nov-[ADDRESS_826228] Manual.  
6.3. Measures to Minimize Bias: Randomization and Blinding  
 
IWRS  After a participant  signs the ICF at Screening, site personnel will register 
the p articipant  in the interactive web response system (IWRS) . 
Upon successful completion of the Screening module the system will 
assign the participant  a unique participant number ( Subject ID ).  
Randomization will be performed as double blind, Central 
Randomization.    
Upon successful completion of randomization in t he IWRS the system 
will determine the correct study intervention kit type to dispense. Once a 
participant  is randomized to a treatment arm, the randomization will 
remain documented as such. The system will never reuse th e same  
randomization number.  
The sys tem will then determine which study intervention  kit of that type 
is available for dispensing and inform the study site to dispense that kit.  
The kit assigned will correspond to the correct treatment for the 
participant . 
Study intervention will be dispense d at the study visits as summarized in 
the SoA.   
 
Blind break 
(IWRS)  This is a double -blind study in which participants/Investigators/raters, etc. 
are blinded to study interven tion. The IWRS will be programmed with 
blind -breaking instructions. In case of an emergency, the Investigator has 
the sole responsibility for determining if unblinding of a participant’s 
intervention assignment is warranted. Participant safety must always be 
the first consideration in making such a determination. If the Investigator 
decides that unblinding is warranted, the Investigator should make every 
effort to contact [CONTACT_67806]/or Sponsor prior to unblinding a 
participant’s intervention as signment unless this could delay emergency 
treatment for the participant. If a participant’s intervention assignment is 
unblinded, the Sponsor must be notified within [ADDRESS_826229] be recorded . 
CONFIDENTIAL    Protocol BNC210.012              Version 4.0 (US) , 17-Nov-2022 
 
 31   
  
 
 
 
 
 
  
 
   
  
 
 
  
 
  
  
   
 
 
  
 
 
 
 
 
  
 
  
 
 
 
 
   
 
 
 
 

CONFIDENTIAL    Protocol BNC210.012              Version 4.0 (US) , 17-Nov-[ADDRESS_826230] of care treatments as directed by 
[CONTACT_620786].  
6.7. Treatment of Overdose  
For this study, any dose of BNC210/placebo  greater than 1,800 mg  within a 24-hour time period 
will be considered an overdose.  
In the event of an overdose, the Investigator should:  
• Contact [CONTACT_27465].  
• Evaluate the participant to determine, in consultation with the Medical Monitor, whether 
study intervention should be interrupted.  
• Closely monitor the participant for any AE/SAE and laboratory abnormalities until they 
have resolved or stabilized.  
• Document the quantity of the excess dose as well as the duration of the overdose.  
6.8. Concomitant Therapy  
Any medication or vaccine (including over -the-counter or prescription medicines, recreational 
drugs, vitamins, and/or herbal supplements) or other specific categories of interest that the 
participant is receiving at the time of Screening  or receives during the study must be recorded 
along with:  
• Reason for use  
• Dates of administration including start and end dates  
• Dosage information including dose and frequency  
The Medical Monitor should be conta cted if there are any questions regarding concomitant or 
prior therapy.  
Use of any investigational drug , vaccine  or invasive device within 30 days prior to Screening and 
at any point during the study is prohibited.  
Inducers of cytochrome P450 3A4 should not be used within 30 days  of Screening and their use 
is prohibited during the study. This includes, but is not limited to: carbamazepi[INVESTIGATOR_050], phenytoin, 
oxcarbazepi[INVESTIGATOR_050], barbiturates, phenobarbital, butalbital, St. John's wort, rifampi[INVESTIGATOR_2513], rifabutin, 
efavirenz, nevirapi[INVESTIGATOR_050], pi[INVESTIGATOR_051],  troglitazone, corticosteroids by [CONTACT_620787]  (see 
Appendix [ADDRESS_826231]) .   
 
CONFIDENTIAL    Protocol BNC210.012              Version 4.0 (US) , 17-Nov-2022 
 
 33 Moderate to strong inhibitors of cytochrome P450 3A4 should not be used within two weeks of 
Screening and their use is prohibited during the study.  These i nclude grapefruit juice, verapamil, 
diltiazem, fluvoxamine, fluconazole and itraconazole and HIV antivirals  (refer to the following 
website for a more extensive list https://drug -intera ctions.medicine.iu.edu/MainTable.aspx ).  
Participants that are under consideration for the study and are being treated with a n 
antidepressant medication, must have discontinued the medication for at least 30 days  prior t o 
Screening  (as per exclusion criterion #19) and be titrated off their medication in accordance with 
current prescribing guidelines. Participants must also have discontinued the use of alprazolam, 
flunitrazepam and chronic daily use of other benzodiazepi[INVESTIGATOR_050] s for at least [ADDRESS_826232] 5 
days prior to Screening.  The withdrawal of these medication s is at the discretion of the 
participant in consultation with their  primary physician and falls outside the scope of this study 
protocol.  
The use of antidepressants and psychotropic  medication s are also prohibited during all stages of 
the study. This includes, but is not limited to, mood stabilizers, stimulants, antipsychotics, 
anticonvulsant drugs (including gabapentinoids), hypnotics, benzodiazepi[INVESTIGATOR_1651], methylphenidate, 
doxazosin, prazosin, clonidine, fir st generation sedating H1 antihistamines, quetiapi[INVESTIGATOR_050], 
eszopi[INVESTIGATOR_11123], zolpi[INVESTIGATOR_123200] -release and acetylcholinesterase inhibitors.   
The use of non -prescription medications (including herbal medications) will be discouraged 
during the course of the study. Prescription medications should be limited and avoided if 
possible, but will be allowed where clinically indicated, e.g., for treatme nt of AEs or pre -existing 
medical conditions documented at Screening.   
Ongoing long -term supportive counseling is allowed only if the participant  commenced therapy 
> [ADDRESS_826233] be promptly notified in order to assess the participant ’s suitability for continued 
study participation.  
6.8.1.  Rescue Medic ations for  Insomnia  
Only the use of certain n onbenzodiazepi[INVESTIGATOR_620760] (e.g., zolpi[INVESTIGATOR_620761] -release [up 
to 10 mg at bedtime], zaleplon [up to 20 mg at bedtime]), melatonin, or ramelteon for sleep are 
allowed.  The date and time of rescue medication administration as well as the name [CONTACT_620808].  
 
CONFIDENTIAL    Protocol BNC210.012              Version 4.0 (US) , 17-Nov-2022 
 
 34 7. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal  
The process for d iscontinuation of specific sites or the study as a whole are detailed in Appendix 
1. 
7.1. Discontinuation of Study Intervention  
In rare instances, it may be necessary for a participant  to permanently discontinue study  
intervention . If study intervention is permanently  discontinued, the pa rticipant  will not  remain in 
the study. See the S oA for evaluations that need to be completed  at the time of discontinuation of 
study intervention (Early Termination visit ). 
7.1.1.  Liver Chem istry Stoppi[INVESTIGATOR_620762] a participant meets one of the conditions outlined  in the algorithm  or in the presence of 
abnormal liver chemistries not meeting protocol -specified stoppi[INVESTIGATOR_620763].   Study interventio n restart or rechallenge after 
liver chemistry stoppi[INVESTIGATOR_620764] . 
Phase 2 Liver Chemistry Stoppi[INVESTIGATOR_620765]: ALT = alanine transaminase; AST = aspartate transaminase,  INR = international normalized ratio; 
SAE = serious adverse event; Tbili = total bilirubin , ULN = upper limit of normal.  
Liver Safety : Suggested  Actions and Follow -up Assessments can be found in  Appendix 5 .  

CONFIDENTIAL    Protocol BNC210.012              Version 4.0 (US) , 17-Nov-2022 
 
 35 7.1.2.  QTc Stoppi[INVESTIGATOR_2121]  
A participant who meets  the bulleted criterion  based on the average of triplicate  ECG readings 
will be withdrawn from study intervention.  
• QTc >  500 msec OR change from Baseline of QTc >  60 msec  
For participants with underlying bundle branch block, follow the discontinuation criteria listed 
below : 
Baseline QTc with Bundle Branch Block  Discontinuation QTc Threshold with 
Bundle Branch Block  
< 450 msec  > 500 msec  
450 to 480 msec  ≥ 530 msec  
If a clinically significant finding is identified (including, but not limited to changes from 
Baseline in QT interval corrected using Fridericia’s formula [QTcF] ) after enrollment, the 
Investigator or qualified designee will determine if the participant  can continue in the study  and 
if any change in participant  management is needed . This review of the ECG printed at the time of 
collection  must be documented . Any new clinically relevant finding should be reported as an AE. 
7.1.3.  Suicidal Behavior Stoppi[INVESTIGATOR_2121]  
A participant who meets  any of the  bulleted criteria  below will be withdrawn from study 
intervention.  
• Any new suicidal behavior since Screening, as disclosed by [CONTACT_620788] C -SSRS 
• Any suicidal ideation with intent (yes to item 4 and/or 5) since Screening, as disclosed by 
[CONTACT_620789] C -SSRS  
• A score > [ADDRESS_826234] be obtained prior to re -commencing study intervention . Dose 
reductions will not be allowed.  
7.2. Participant Discont inuation/Withdrawal from the Study  
• A participant  may withdraw from the study at any time at his/her own request or may be 
withdrawn at any time at the discretion of the Investigator  for safety, behavioral , or 
compliance  reasons . This is expected to be uncommon . 
• At the time of discontinuing from the study, if possible, an Early Termination  visit should 
be conducted, as shown in the S oA.  
• The participant  will be permanently discontinued both from the study intervention  and 
from the study at that time . 
CONFIDENTIAL    Protocol BNC210.012              Version 4.0 (US) , 17-Nov-2022 
 
 36 • If the participant  withdraws consent  for disclos ure of future information, the Sponsor 
may retain and continue to use any data collected before such a withd rawal of consent . 
• If a participant  withdraws from the study, he/she may request destruction of any samples 
taken and not tested , and the Investigator must document this in the site study records . 
7.3. Lost to Follow up  
A participant  will be considered lost to follow -up if he /she repeatedly fails to return for 
scheduled visits and is unable to be contact[CONTACT_9298].  
The following actions must be taken if a participant  fails to return to the study site  for a required 
study visit:  
• The site must attempt to contact [CONTACT_47995] m issed visit as soon as 
possible and counsel the participant  on the impor tance of maintaining the assigned visit 
schedule and ascertain whether or not the participant  wishes to and/or should continue in 
the study.  
• Before a  participant  is deemed lost to f ollow up, the Investigator or designee must make 
every effort to regain con tact with the participant  (where possible, 3 telephone calls and , 
if necessary , a certified letter to the participant ’s last known mailing address or local 
equivalent methods). These contact [CONTACT_13140] ’s 
medical record . 
• Should the participant  continue to be unreachable, he/she will be considered to have 
withdrawn from the study .  
CONFIDENTIAL    Protocol BNC210.012              Version 4.0 (US) , 17-Nov-2022 
 
 37 8. Study Assessments and Procedures  
• Study procedures and their timing are summarized in the SoA.  Protocol  waiver s or 
exemptions are not allowed.  
• Immediate  safety concerns  should be discussed with the Medical Monitor  immediately 
upon occurrence or awareness to determine if the participant should continue or 
discontinue study intervention . 
• Adherence to the stud y design requirements, including those specified in the SoA, is 
essential and required for study conduct.  
• All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility criteria. The Investigator will maintain a screening log to 
record details of all participants screened and to confirm eligibility or record reasons for 
screening failure, as applicable.  
  
 
 
 
   
• As a guide, diagnostic and efficacy assessment scales such as CAPS -5, PCL -5, SCID -5-
CT and SCID -PD (Screening only) and LEC -5 (Screening only) should be administered 
first, followed by [CONTACT_73789], anxiety and suicidality scale s (i.e., MADRS, HAM -A, C -
SSRS). Other efficacy scales such as CGI -S/I, PGI -S/I, SDS, and ISI should then be 
administered prior to remaining safety and diagnostic assessments such as clinical labs, 
physical examinations and ECGs. This order of procedures sh ould be followed 
throughout the study where possible.  
• At the Week 2  visit, assessment of AEs  and recording of concomitant medications should 
be performed , as well as a general assessment of how the participant is managing their 
dosing with the study interv ention.  The Week 2 visit can be performed either at the study 
site or via phone/video call with the study participant.  
• At the Week [ADDRESS_826235], ALP, and bilirubin (direct and total).  Participants can 
have this testing performed at the study site for analysis at the central laboratory or 
testing can be performed at a local laboratory.  There is no requirement for the participant 
to attend the study site to have  this testing performed if a suitable alternative arrangement 
has been agreed with the study site (e.g. , home health visit).  
• All Investigator -rated assessm ents and Patient Recorded Outcomes (PROs) will be 
completed using  paper  assessment scales . 
• Where possible, study assessments will be made available for remote administration in 
cases where restrictions, as a consequence of COVID -19 or other natural disasters, 
prevent participants from attending clinic visits.  PROs will be pr ovided to participants as 
paper versions to be completed at the appropriate time point and returned to the study site 
upon completion.  Laboratory assessments, inclusive of samples for concentration of 

CONFIDENTIAL    Protocol BNC210.012              Version 4.0 (US) , 17-Nov-[ADDRESS_826236] will not be considered protocol 
deviations.  
• Where restrictions due to COVID -19 or other natural disaster s, prevent participants from 
performing study  visits in person , a participant or verified representative of the 
participant , may attend the  study site t o return/obtain study intervention . If Sponsor 
approved procedures are in place at a study site, study intervention may also be delivered 
to a participant’s home.   
• Analyte results  that could unblind the study will not be reported to study  sites or other 
blinded personnel.  
• The maximum amount of blood collected from each part icipant over the duration of the 
study, including any extra assessments that may be required, should  not exceed  110 mL. 
• On days where study visits occur, participants should continue to take their morning dose 
of study intervention at their schedule d time,  even if prior to attending the study site  for 
the scheduled visit. If the scheduled time of dosing coincides with a study visit, 
participants can take their dose of study intervention during the study  visit.   
• Dispensing of study intervention should occur  last, after all study tests and assessments 
have been completed for a specified study visit. All visits should be scheduled to occur at 
approximately the same time of day.  
• Participant s may attend an unscheduled visit at any time. All assessments completed  
during an unscheduled visit must be captured in the eCRF. This includes the results of all 
pathology tests scheduled by [CONTACT_737].  
• Visits scheduled due to increased safety monitoring in line with Section 7.[ADDRESS_826237] be 
captured as an unscheduled visit .  
• A visit with a participant ’s primary physician ( i.e., not a study Investigator) is not 
considered an unscheduled visit. Similarly, hospi[INVESTIGATOR_620766]. Assessments completed by [CONTACT_620790] . 
8.1. Efficacy Assessmen ts 
Planned time points for all efficacy  assessments are provided in the SoA.  
8.1.1.  Clinician -Administered PTSD Scale for the DSM -5 (CA PS-5) 
The CAPS -[ADDRESS_826238] month . Information about the frequency and intensity of each item is 
combined into a severity rating, and the CAPS -5 total symptom severity  score is calculated by 
[CONTACT_620791] 20 PTSD symptoms in the DSM -5 (National Centre for PTSD ).  
The CAPS -5 interview should be audio recorded using the pro vided iPhone at every study visit.  
CONFIDENTIAL    Protocol BNC210.012              Version 4.0 (US) , 17-Nov-[ADDRESS_826239] for DSM -5 (PCL -5) 
The PCL -5 is a 20 -item self -report assessment of the 20 DSM -5 symptoms of PTSD ( National 
Centre for PTSD ). Each symptom is rated on a scale from 0 (not at all) to 4 (extremely).  
8.1.3.  Clinical Global Impression Scales – Severity and Improvement (CGI -S/I) 
The CGI -S is a rating scale designed to assess the severity of the particip ant’s symptoms, and the 
CGI-I is designed to assess the change in the participant ’s condition since the initial assessment. 
Severity is rated on the CGI -S from 1 (normal, not at all ill) to 7 (among the most extremely ill 
of participant s). The changes in t he participant ’s condition are rated on the CGI -I from 1 (very 
much improved) to 7 (very much worse).  
8.1.4.  Patient Global Impression Scales – Severity and Improvement (PGI -S/I) 
The PGI -S is a self -rating scale designed to assess the severity of the participant ’s symptoms, 
and the PGI -I is designed to assess the change in the participant ’s condition since the initial 
assessment. Severity is rated on the CGI -S from 1 (normal) to 4 (severe). The changes in the 
participant ’s condition are rated on the CGI -I from 1 ( very much better) to 7 (very much worse).  
8.1.5.  Hamilton Anxiety Rating Scale (HAM -A) 
The HAM -A is an interview questionnaire that measures severity of anxiety symptoms based on 
14 parameters, including anxious mood, tension, fears, insomnia, somatic complaints and 
behavior during the interview ( Hamilton, 1959 ). Each  parameter is rated on a scale of 0 (not 
present) to 4 (very severe).  
8.1.6.  Montgomery -Åsberg Depression Rating Scale (MADRS)  
The MADRS is a 10-item self -diagnostic and clinician -rated questionnaire to measure the 
presence and severity of depressive epi[INVESTIGATOR_620767]: 1) apparent 
sadness; 2) reported sadness; 3) inner tension; 4) reduced sleep; 5) reduced appetite; 6) 
concentration difficulties; 7) lassitude; 8) inability to feel; 9) pessimistic thoughts; and 10) 
suicidal thoughts ( Williams and Kobak, 2008 ). The rater must decide whether the rating lie s on 
defined scale steps (0, 2, 4, 6) or between them (1, 3, 5).  
8.1.7.  Sheehan Disability Scale (SDS)  
The SDS is a rating scale designed to measure impairment in three domains: work/school, social 
life, and family life/home responsibilities. Each item is rated o n a scale of 0 (not at all) to 10 
(extremely), for a total score of 0 to 30.  
8.1.8.  Insomnia Severity Index (ISI)  
The ISI is a brief self -report instrument measuring both nocturnal and diurnal symptoms of 
insomnia ( Morin 1993 ).  The ISI comprises seven items, each scored from 0 to 4, assessing the 
perceived severity of difficulties initiating sleep, staying asleep, and early morning awakenings, 
satisfaction  with current sleep pattern, interference with daily functioning, noticeability of 
impairment attributed to the sleep problem, and degree of distress or concern caused by [CONTACT_620792].  The scores from each of the 7 questions are added up to get a tot al score of 0 to 28.  
 
 
CONFIDENTIAL    Protocol BNC210.012              Version 4.0 (US) , 17-Nov-2022 
 
 40 8.2. Safety Assessments  
Planned time points for all safety assessments are provided in the SoA.  
8.2.1.  Physical Examinations  
• A complete physical examination will include, at a minimum, assessments of the general 
appearance , skin and lymphatics , eyes, ears, nose, throat , cardiovascular system , 
respi[INVESTIGATOR_2133] , abdomen/gastrointestinal system , musculoskeletal and neurological 
systems.  Other body systems may also be examined as  required . Height and weight will 
also be measured and recorded  at the time points specific in the SoA . 
• An abbreviated  physical examination will include, at a minimum, assessments of the 
eyes, ears, nose, throat, cardiovascular system, respi[INVESTIGATOR_2133], and 
abdomen/gastrointestinal system. Other body systems may also be examined as required . 
• Investigators should pay special attention to clinical signs related to previous serious 
illnesses.  
• Clinically significant changes from first dose of study intervention  will be recorded as 
AEs.  
8.2.2.  Vital Signs  
• Body  temperature, pulse rate, respi[INVESTIGATOR_697], and systolic and diastolic blood pressure 
will be assessed.  
• Blood pressure and pulse measurements will be assessed in a sitting pos ition with a 
completely automated device. Manual techniques will be used only if an automated 
device is not available.  
• Blood pressure and pulse measurements should be preceded by [CONTACT_2669] [ADDRESS_826240] 
in a seated position for the participant in a quiet setting without distractions (e .g., 
television,  cell phones).  
8.2.3.  Electrocardiograms  
• Triplicate  12-lead ECG s will be obtained as outlined in the SoA using an ECG machine 
that automatically calculates the heart rate and measures PR, QRS, QT, and QTc 
intervals. Refer to Section 7.1.2 for QTc withdrawal criteria and any additional QTc 
readings that may be necessary.  
• At each time point, 3 individual ECG tracings should be obtained in succession, 
appro ximately  2 minutes apart.  
• One repeat is allowed for screening  purposes if abnormal findings are observed. The 
repeat must also be completed in triplicate.  
• Participants must be resting in a semi -supi[INVESTIGATOR_620768] 5 minutes 
prior to obtaining ECG.   
• The same ECG machine should be used for all reco rdings from an individual participant, 
where possible.   
CONFIDENTIAL    Protocol BNC210.012              Version 4.0 (US) , 17-Nov-2022 
 
 41 • ECGs will be read by [CONTACT_620793].   
• QTcF values will be derived from the data available and the average QTcF will be used 
when assessing eligibility and treat ment withdrawal . 
For safety monitoring purposes, the Investigator or designee must review, sign and date all ECG 
tracings.  Paper copi[INVESTIGATOR_620769] 's clinical file as part of 
the permanent record.  The ECG intervals and interpretation will be recorded on the appropriate 
eCRF.  
Paper ECG recordings should be photocopi[INVESTIGATOR_620770] a permanent source document.  
The Sponsor reserves the right to request copi[INVESTIGATOR_620771] . 
8.2.4.  Clinical Safety Laboratory Assessments  
• See Appendix [ADDRESS_826241] of clinical laboratory tests to be performed and to the So A for 
the timing and frequency.  
• The Investigator must review the laboratory report, document this review, and record any 
clinically significant  changes occurring during the study  as an  AE. The l aboratory reports 
must be filed with the source documents.  
• Abnormal laboratory findings associated with the underlying disease are not considered 
clinically significant unless judged by [CONTACT_465731]'s condition.  
• All laboratory tests with values considered cli nically significantly abnormal during 
participation in the study or within [ADDRESS_826242] dose of study intervention 
should be repeated until the values return to normal or baseline or are no longer 
considered clinically significant by [CONTACT_47998].  
o If clinically significant  values do not return to normal/baseline within a period of time 
judged rea sonable by [CONTACT_737], the etiology should be identified , and the 
Medical Monitor/ Sponsor notified . 
o All protocol -required laboratory tests, as defined in Appendix 2, must be conducted in 
accordance with the Laboratory Manual and the SoA.  
o If laborator y values from non -protocol specified laboratory tests performed at the 
institution’s local laboratory require a change in participant management or are 
considered clinically significant by [CONTACT_737] (e .g., SAE or AE or dose 
interruption ), then the r esults must be recorded . 
8.2.5.  Suicidal Ideation and Behavior Risk Monitoring  
BNC210 is considered to be a Central Nervous System ( CNS ) active intervention. Patients with 
PTSD may occasionally develop suicidal ideation or behavior.  
Participants  being treated with study intervention  should be monitored appropriately and 
observed closely for suicidal ideation and behavior or any other unusu al changes in behavior, 
especially at the beginning and end of the course of intervention. Participants who experience 
CONFIDENTIAL    Protocol BNC210.012              Version 4.0 (US) , 17-Nov-2022 
 
 42 signs of suicidal ideation or behavior, should undergo a risk assessment. All factors contributing 
to suicidal ideation or behavior  shoul d be evaluated and consideration should be given to 
discontinuation of the study intervention.   
When informed consent or assent has been given, families and  caregivers of participants  being 
treated with study intervention  should be alerted about the need to monitor participants  for the 
emergence of unusual c hanges in behavior, as well as the emergence of suicidal ideation and 
behavior and to report such symptoms immediately to the study Investigator.  
Baseline assessment of suicidal ideation and behavior/ intervention emergent suicidal ideation 
and behavior  will be monitored during the study using the C -SSRS.  
The C -SSRS is a suicidal ideation rating scale designed to identify behaviors that may be 
indicative of a patient’s intent to commit suicide. The scale is administered via a semi -structured 
interview and m easures both passive and active suicidal ideation and the intensity and duration 
of the ideation. Both suicidal and non -suicidal self -injurious behavior is also assessed.  
8.3. Adverse Events (AEs), Serious Adverse Events (SAEs), and Other 
Safety Reporting  
The definitions of AEs and SAEs can be found in Appendi x 3. 
The definitions of unsolicited and solicited AEs can be found in Appendix 3 . 
AEs will be reported by [CONTACT_2299] (or, when appropriate, by a caregiver, surrogate, or the 
participant’s legally authorized representative).  
The Investigator and any qualified designees are responsible for detecting, documenting, and 
recording events that meet the definition of an AE or SAE and remain responsible for following 
up all AEs /SAEs.  
The method of recording, evaluating, and assessing causality of AEs and SAEs and the 
procedures for completing and transmitting SAE reports are provided in Appendix 3. 
8.3.1.  Time Period and Frequency for Collecting AE and SAE Information  
All SAEs will be collected from the signing of the ICF until the Follow -up visit  at the time points 
specified in the SoA.  
All AEs will be collected from the start of intervention  until the Follow -up visit  at the time 
points specified in the SoA.  Medical occurrences that begin before the start of study intervention 
but after obtaining informed consent will be recorded as Medical History/Current Medical 
Conditions, not as AEs.  
All SAEs will be recorded and r eported to the Sponsor or designee immediately and under no 
circumstance should this exceed 24 hours, as indicated in Appendix 3. The Investigator will 
submit any updated SAE data to the Sponsor within 24  hours of it being available.  
Investigators are not obligated to actively seek information on AEs or SAE s after conclusion of 
the study participation . However, if the Investigator learns of any SAE, including a death, at any 
time after a participant has been discharged from the study, and he/she considers the event to be 
reasonably related to the study intervention or study participation, the Investigator must promptly 
notify the Sponsor . 
CONFIDENTIAL    Protocol BNC210.012              Version 4.0 (US) , 17-Nov-2022 
 
 43 8.3.2.  Method of Detecting AEs and SAEs  
Care will be taken not to introduce bias when detecting AEs and/or  SAEs. Open -ended and 
non-leading verbal questioning of the participant is the preferred method to inquire about 
AE occurrences . 
8.3.3.  Follow -up of AEs and SAEs  
After the initial AE/SAE report, the Investigator is required to proactively follow each 
participant at subsequent visits/contacts. All SAEs  will be follow ed until resolution, stabilization, 
the event is otherwise explained, or the participant is lost to follow -up (as defined in Sectio n 
7.3). Further information on follow -up procedures is provided  in Appendix  3. 
8.3.4.  Regulatory Reporting Requirements for SAEs  
• Prompt notification by [CONTACT_46352] a n SAE is essential so that legal 
obligations and ethical responsibilities towards the safety of participants and the safety of 
a study intervention under clinical investigation are met.  
• The Sponsor has a legal responsibility to notify both the local regulat ory authority and 
other regulatory agencies about the safety of a study intervention under clinical 
investigation. The Sponsor will comply with country -specific regulatory requirements 
relating to safety reporting to the regulatory authority, Institutional  Review Board (IRB)  
and Investigators.  
• An Investigator who receives an investigator safety report describing a n SAE or other 
specific safety information ( e.g., summary or listing of SAEs) from the Sponsor will 
review and then file it along with the Investi gator’s Brochure and will notify the IRB, if 
appropriate according to local requirements.  
8.3.5.  Pregnancy  
• Details of all pregnancies in female parti cipants and female partners of male participants  w
ill be collected after the start of study intervention and until [ADDRESS_826243] dose of 
study intervention is administered . 
• If a pregnancy is reported  in a female participant or female partner of male participant 
(after obtaining the necessary signed informed consent from the female partner ), the 
Investigator will record pregnancy information on the appropriate form and submit it  
promptly , within [ADDRESS_826244]  information  can be 
found in Appendix 3, Section 10.3.4.  
• While pregnancy it self is not considered to be an AE or SAE, any pregnancy 
complication or elective termination of a pregnancy for medical reasons will be reported 
as an AE or SAE.  
• Abnormal pregnancy outcomes (e .g., spontaneous abortion, fetal death, stillbirth, 
congenital anomalies, ectopic pregnancy) are considered SAEs  and will be reported as 
such. 
CONFIDENTIAL    Protocol BNC210.012              Version 4.0 (US) , 17-Nov-2022 
 
 44 • The participant /pregnant female partner  will be followed to determine the outcome of the 
pregnancy. The Investigator will collect follow -up information on the 
participant /pregn ant female partner  and the neonate and the information will be 
forwarded to the Sponsor.  
• Any post -study pregnancy -related SAE considered reasonably related to the study 
intervention by [CONTACT_620794] n 8.3.4 . While the Investigator is not obligated to actively seek this information in 
former study participants /pregnant female partner , he or she may learn of an SAE through 
spontaneous reporting.  
• Any female participant who becomes pregnant while participating in the study will 
discontinue study intervention and be withdrawn from the stud y. 
8.4. Pharmacokinetics  
• Whole blood  samples of approximately 4 mL will be collected for measurement of 
plasma  concentrations of BNC210  as specified in the SoA. Samples will be used to 
evaluate the  pharmacokinetics  of BNC210.  
• As the study is double -blind, samples will be collected from all participants but only 
those allocated to the BNC210 treatment arm will have their samples analyzed at the 
appropriate time.  
• Instructions for t he collection and handling of biological samples will be provided by [CONTACT_620795] .  
8.5. Genetics  
Genetics are not evaluated in this stud y. 
8.6. Biomarkers  
Biomarkers are not evaluated in this study.  
8.7. Immunogenicity Assessments  
Not applicable.  
8.8. Health Economics OR Medical Resource Utilization and Health 
Economics  
Health economics OR Medical res ource utilization and health economics parameters are not 
evaluated in this study.  
CONFIDENTIAL    Protocol BNC210.012              Version 4.0 (US) , 17-Nov-2022 
 
 45 9. Statistical Considerations  
9.1. Statistical Efficacy Hypotheses  
The primary objective of the current study is to evaluate the efficacy of B NC210 on Investigator -
rated total symptom severity of PTSD in adult participants  with PTSD.  
• The null hypothesis for the primary efficacy endpoint of equality of B NC210 and placebo is:  
H01: Mean change in CAPS -5 Total Symptom Severity Scores between Baseline and 
Week  12 in the two treatment groups are equal.  
The key secondary objectives of the current study and their respective null hypotheses of the 
equality of B NC210 and placebo are:  
• To evaluate the efficacy of B NC210 on Investigator -rated global functioning in adult 
participants  with PTSD.  
H02: Mean change in CGI -S between Baseline and Week 12 in the two treatment groups 
are equal.  
• To evaluate the efficacy of BNC210 on patient -reported social functioning in adult 
participants with PTSD.  
• H03: Mean change in SDS between Baseline and Week 12 in the two treatment groups are 
equal.  
Other  secondary objectives of the current study and their respective null hypotheses of the 
equality of B NC210 and placebo are:  
• To evaluate the efficacy of B NC210 on Investigator -rated symptom cluster s of PTSD in adult 
participants  with PTSD.  
H04: Mean change in  CAPS -5 Intrusion Severity Scores (Cluster B) between Baseline and 
Week 12 in the two treatment groups are equal.  
H05: Mean change in CAPS -5 Avoidance Severity Scores (Cluster C) between Baseline 
and Week 12 in the two treatment groups are equal.  
H06: Mean  change in CAPS -5 Negative Alterations in Cognition s and Mood Severity 
Scores (Cluster D) between Baseline and Week 12 in the two treatment groups are equal.  
H07: Mean change in CAPS -5 Arousal and Reactivity Severity Scores (Cluster E) 
between Baseline and Week 12 in the two treatment groups are equal.  
• To evaluate the response rate and remission rate of BNC210 on Investigator -rated total 
symptom severity of PTSD in adult participants with PTSD.  
H08: Proportion of participants who achieve a ≥30% i mprovement in CAPS -5 Total 
Symptom Severity Scores between Baseline and Week 12 in the two treatment groups are 
equal.  
H09: Proportion of participants  who achieve a ≥50% improvement in CAPS -5 Total 
Symptom Severity Scores between Baseline and Week 12 in th e two treatment groups are 
equal.  
CONFIDENTIAL    Protocol BNC210.012              Version 4.0 (US) , 17-Nov-2022 
 
 46 H10: Proportion of participants  who achieve a score ≤11 on the CAPS -5 Total Symptom 
Severity Score between Baseline and Week 12 in the two treatment groups are equal . 
• To evaluate the efficacy of B NC210 on Investigator -rated global functioning in adult 
participants  with PTSD.  
     H11: Mean scores of the CGI -I at Week 12 in the two treatment groups are equal.  
• To evaluate the efficacy of B NC210 on Investigator -rated  symptoms of anxiety in adult 
participants  with PTSD.  
H12: Mean change in HAM -A Total Scores between Baseline and Week 12 in the two 
treatment groups are equal.  
• To evaluate the efficacy of BNC210 on Investigator -rated  symptoms of depression in adult 
participants with PTSD.  
H13: Mean change in MADRS Total Scores between Baseline and Week 12 in the two 
treatment groups are equal.  
• To evaluate the efficacy of BNC210 on patient -reported symptoms of PTSD in adult 
participants with PTSD.  
H14: Mean change in PCL -5 Total Scores between Baseline and Week 12 in  the two 
treatment groups are equal.  
• To evaluate the efficacy of B NC210 on patient -reported global functioning in adult 
participants  with PTSD.  
   H15: Mean change in PGI -S between Baseline and Week 12 in the two treatment groups 
are equal.  
     H16: Mean scores of the PGI -I at Week 12 in the two treatment groups are equal.  
• To evaluate the efficacy of B NC210 on patient -reported sleep quality in adult participants  
with PTSD.  
H17: Mean change in ISI between Baseline and Week 12 in the two treatment group s are 
equal.  
9.1.1.  Multiplicity Adjustment  
Because this is a Phase 2 study, the level of significance will be set at 0.05 for primary and 
secondary endpoints with no adjustment for multiple comparisons.  
 
 
 
 
 
CONFIDENTIAL    Protocol BNC210.012              Version 4.0 (US) , 17-Nov-2022 
 
 47 9.2. Analysis Sets  
The following analysis populations are planned for this study:  
• Safety Population (SAF): The safety population includes all participants  who receive any 
amount of t he study intervention . The safety population will be used for the analysis of 
the safety endpoints. Participants  will be analyzed by [CONTACT_147246].  
• Intent -to-Treat Population (ITT): The ITT population includes all randomized 
participants. Parti cipants will be analyzed by [CONTACT_620796].  
• Modified Intent -to-Treat Population (mITT): The mITT population includes all 
participants  in the ITT population who receive any amount of the study intervention  and 
have at least one post -baseline efficacy  assessment .  Participants will be analyzed by 
[CONTACT_29673].  
• Per-Protocol Population (PP): The per -protocol population will include participants from 
the mITT population who have no major protocol deviations. Before data are released for 
statistical analysis, a blinded review of all data will be performed in conjunction with the 
Sponsor to identify protocol deviations that may potentially affect the results. At this 
time, it will be determined if participants and/or data should be excluded  from the PP 
population. The list of participants or observations to be excluded from the PP population 
will be provided in the Clinical Study Report. Participants will be analyzed by 
[CONTACT_620796].  
• PK Population (PK): The PK population will includ e all participants  from the safety 
population who have a valid concentration measurement . 
9.3. Statistical Analyses  
9.3.1.  General Considerations  
This section presents a summary of the planned statistical analyses. A Statistical Analysis Plan 
(SAP) that describes the details of the analyses to be conducted will be written prior to the study 
database being locked. 
Unless otherwise indicated, all testing of statistical significance will be two -sided and a 
difference resulting in a p value of ≤0.[ADDRESS_826245] deviation (SD), 
median, minimum, and maximum. For categorical variables, these statistics will typi[INVESTIGATOR_620772].  
9.3.2.   Study Participant and Demographics  
[IP_ADDRESS].    Disposition and Withdrawals  
The number of participants  randomized, co mpleting, and withdrawing, along with reasons for 
withdrawal, will be tabulated overall and by [CONTACT_1570]. The number of participan ts in each 
analysis population will be reported.  
 
CONFIDENTIAL    Protocol BNC210.012              Version 4.0 (US) , 17-Nov-2022 
 
 48 Completers will be recorded as Week 12 completers and Week 15 complete rs. Week 12 
completers will be defined as all participants who complete the randomized treatment period, 
while Week 15 completers will be defined as those who complete the randomized treatment 
period as well as the Follow -up visit.  
[IP_ADDRESS].   Protocol Deviations  
Protocol deviations will be identified and classified as important or non -important for statistical 
analysis purposes before unblinding and will be summarized or listed as appropriate. Important 
protocol deviations that might affect efficacy dat a will be used to exclude participants  from the 
per protocol analysis.  
[IP_ADDRESS].   Demographics and Other Baseline Characteristics  
The following analyses will be conducted for all analysis populations : 
• Demographic variables will include age, sex, height, and weight. Information on race and 
ethnicity will be collected for any eventual analysis of differences in response to the 
study intervention in accordance with local regulatory requirements.  
• Baseline participant characteristics will include medical history includin g confirmation of 
PTSD diagnosis, index trauma event  and time since index trauma event. Baseline 
evaluation of the CAPS -5 Total Severity Score, PCL -5 total score, CGI -S score, PGI -S 
score, MADRS total score, HAM -A total score, SDS total score, and ISI tota l score will 
also be reported.  
• Prior and concomitant medications will be summarized by [CONTACT_1570], by [CONTACT_620797], classified using World 
Health Organization Drug Dictionary (WHO -DD) Anatomical Therapeutic Chemical 
(ATC) classes and preferred terms.  
9.3.3.  Primary and Key Secondary Endpoint/Estimand Analys es 
The primary efficacy endpoint for the current study will be the change in CAPS -5 Total Sy
mptom Severity Scores from Baseline to Week 12 for participants receiving BNC210 compared 
to participants receiving placeb o. The analysis of the primary efficacy endpoint will be evaluated 
for the mITT population according to the planned treatment.  
Taking into consideration the potential for missing data, t he primary and key secondary 
endpoint s will be assessed for the mITT population according to the planned treatment  with a 
Mixed Model for Repeated Measures (MMRM) with multiple  imputation  (MI) . Each  model will 
include fixed effects for treatment, interaction between treatment and visit, center , and covariate 
for Baseline score. MMRM with no MI will be used as a supportive analysis for the primary  and 
key secondary  endpoint s for the mITT and PP populations according to the planned treatment . 
Additionally, a figure with the Least Square s (LS) means ± Standard Error ( SE) of change from 
Baseline in the CAPS -5 Total Symptom Severity Score  in the mITT population  will be presented 
by [CONTACT_6982].  
CONFIDENTIAL    Protocol BNC210.012              Version 4.0 (US) , 17-Nov-2022 
 
 49 9.3.4.  Supportive Analys es for Primary  and Key Secondary  Efficacy Endpoint s 
Supportive analyses will be performed on the primary and key secondary efficacy endpoint s to  
demonstrate the robustness of the conclusions.   Supportive analyses will be conducted using 
MMRM with no MI on the mITT and PP populations.  
Summary statistics on the endpoints  by [CONTACT_6982], including the end of treatment 
visit (Week 12), will also be presented.  
9.3.5.   Multiple Imputation Methods  
Although the assumption of missing at random ( MAR ) is often reasonable in clinical trials, the 
possibility of missing not at random ( MNAR ) data cannot be ruled out. Therefore, analysis valid 
under MNAR will be performed  as the primary analysis . Both MNAR - and MAR -based analyses 
using MI methods will be the basis upon which sensitivity of the analysis to missing da ta are 
assessed.  
Any participants  who withdraws or is discontinued from the study or who misses a scheduled 
visit or assessments up through Week [ADDRESS_826246] analysis methods (MMRM 
for this study), and the different parameter estimates across the datasets are then combined to 
produce unique point estimates, standard errors, and confidence intervals taki ng into account the 
uncertainty of the imputation process.  
In most randomized clinical trials that collect data over time, the great majority of missing data 
follow a monotone pattern. That is, once a participant  has a missing data for some visit, data will 
be missing for all subsequent visits. Typi[INVESTIGATOR_897], there is also a small amount of non -monotone 
missing data (i.e., some participants  have missing values for intermediate visits, but have non -
missing data at subs equent visits).  
The following MI analysis model, based on the MNAR approach, will be used as the primary 
analysis.  
MI with Placebo -Based Imputation  
A placebo -based (jump to control) multiple imputation for missing primary  and key secondary 
endpoints  will be carried out for participants  who withdraw from the study or have missing data 
at a scheduled visit through Week 12, as indicated previously. The imputation has three broad 
components; i) the multiple imputation process for the placebo data; ii) the mult iple imputation 
process for the BNC210 data; and iii) the analysis model that will be used to draw inference 
regarding the primary causal estimands along with the method for combining the results across 
the multiply -imputed datasets. Specific steps for thi s imputation will be outlined in the SAP.  
CONFIDENTIAL    Protocol BNC210.012              Version 4.0 (US) , 17-Nov-2022 
 
 50 9.3.6.  Other Secondary Endpoints Analyses  
All other secondary efficacy endpoints  will be conducted with MMRM with no MI on the mITT 
population only. Summary statistics on the endpoints  by [CONTACT_6982], including the 
end of treatment visit (Week 12), will also be presented .  
For the binary outcomes of the proportion of participants who achieve a) ≥30% improvement; b)  
≥50% improvement; c) remission of PTSD symptoms, the numbe r and proportion will be 
summarized by [CONTACT_6982]. A Pearson’s Chi -squared test or Fisher’s exact test will 
be used to calculate the p -value for the difference between treatment groups.  
9.3.7.  Safety Analyses  
Safety analyses will be  conducted using data from the safety population. Safety variables include 
C-SSRS, AEs, physical examination findings, ECGs, vital signs, and clinical laboratory test 
results (hematology, biochemistry, urinalysis). No formal inferential analyses will be co nducted 
for safety variables unless otherwise noted.  
All AEs will be coded using the Medical Dictionary for Regulatory Activities (MedDRA), 
Version 22.[ADDRESS_826247] dose of stud y 
intervention. The incidence of TEAEs will be summarized by [CONTACT_1570], by [CONTACT_70244] (SOC) and preferred term (PT), by [CONTACT_926], and by [CONTACT_284519]. 
Serious TEAEs and TEAEs leading to study termination will also be sum marized by [CONTACT_2946], PT, 
and treatment group.  
  
 
 
 
 
 
 
9.4. Population Pharmacokinetic (PK) Analysis  
Systemic concentrations of BNC210 will be determined at Weeks 4, 8, and 12. Plasma 
concentration  data will be presented nominally. A data dependent population PK analysis will be 
outlined under a separate analytical plan.  
9.5. Interim Analysis  
No interim analysis is planned for this study.  
9.6. Sample Size Determination  
A sample size of approximately 200 participants (100 participants per treatment arm) is 
calculated to provide ≥80% power to detect a 6 -point difference between BNC210 and placebo 
groups in change from Baseline to Week 12 fo r the CAPS -5 Total Symptom Severity Scores, 

CONFIDENTIAL    Protocol BNC210.012              Version 4.0 (US) , 17-Nov-[ADDRESS_826248] using a two -sided 
significance level of 0.05 and po wer of 80%, 70  participants per treatment group would be 
needed to demonstrate a 6 -point difference between treatment groups, and assuming 30% drop -
out over the 12 -week treatment period leads to a planned sample size of 100 per group.  
 
CONFIDENTIAL    Protocol BNC210.012              Version 4.0 (US) , 17-Nov-2022 
 
 52 10. Supporting Documentation and Operational Considerations  
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight 
Considerations  
10.1.1.  Regulatory and Ethical Considerations  
• This study will be conducted in accordance with the  protocol and with the following:  
o Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and Council for International Organizations of Medical 
Sciences (CIOMS) International Ethical Guidelines  
o Applicable  International Conference on Harmonization  (ICH) Good Clinical Practice 
(GCP) Guidelines  
o Applicable laws and regulations  
• The protocol, protocol amendments, ICF, Investigator ’s Brochure, and other relevant 
documents (e .g., advertisements) must be submitted to an IRB by [CONTACT_577670].  
• The protocol cannot be altered or changed except through a formal protocol am endment, 
which requires written approval f rom the Sponsor.  Any amendments to the protocol will 
require IRB approval  and health authority approval where applicable  and must be signed 
by [CONTACT_620798], except for changes necessary to 
eliminate an immediate hazard to study participants.  
• The Investigator will be responsible for the following:  
o Providing written summaries of the status of the study to the IRB annually or more 
frequently in accordance with the requirements, po licies, and procedures established 
by [CONTACT_1201]  
o Notifying the IRB of SAEs or other significant safety findings as required by [CONTACT_35836] B 
procedures  
o Providing oversight of the conduct of the study at the site and adherence to 
requirements of 21 CFR, ICH guidelines, the IRB, European regulation 536/2014 for 
clinical studies (if applicable) , and all other applicable local regulations  
10.1.2.  Financial Disclosure  
Investigators and Sub-Investigators will provide the Sponsor with sufficient, accurate financial 
information as requested to allow the Sponsor to submit complete and accurate financial 
certification or disclosure statements to the appropriate regulatory authorities. Investigator s are 
responsible for providing information on financial interests during the course of the study and for 
1 year after completion of the study.  
 
CONFIDENTIAL    Protocol BNC210.012              Version 4.0 (US) , 17-Nov-2022 
 
 53 10.1.3.  Informed Consent Process  
• The Investigator or his/her representative will explain the nature of the study , including 
the risks and benefits, to the  participant  and answer all questions regarding the study.  
• Participants must be informed that their participation is voluntary. Participants will be 
required to sign a statement of informed consent that meets the requirements of 21 CFR 
50, local regulation s, ICH guidelines, privacy and data protection  requirements, where 
applicable, and the IRB or study center.  
• The rights and welfare of the participants will be protected by [CONTACT_620799].  
• The medical record must include a statement that written informed consent was obtained 
before the participant was enrolled in the study and the date the written consent was 
obtained. The authorized person  obtaining the informed consent must also sign the ICF.  
• Participants must be reconsented to the most current version of the ICF(s) during their 
participation in the study.  
• A copy of the ICF(s) must be provided to the participant . 
• Informed consent will be o btained before the participant can participate in the stud y. 
• The Investigator or his/her representative must also explain to the participant that they are 
completely free to refuse to enter the study or to withdraw from it at any time . 
• Participants who are rescreened are required to sign a new ICF.  
• Participants who are rescreened will not need to repeat routine clinical laboratory 
assessments or ECGs if an eligible result from the prior screening period has been 
obtained within 21 (+3 days) of randomization into the study.   
• The ICF will contain a separate section that addresses the use of remaining mandatory 
samples for optional exploratory r esearch.  
10.1.4.  Data Protection  
• Participants will be assigned a unique identifier as part of their study participation . Any 
participant records or datasets that are transferred to the Sponsor will contain the 
identifier and information collected as part of the study only; participant nam es or any 
information which would make the participant identi fiable will not be transferred.  
• The participant must be informed that his/her personal study -related data will be used by 
[CONTACT_9324]. The level of di sclosure must 
also b e explained to the participant  who will be required to give consent for their data to 
be used as described in the ICF.  
• The study data entry and study management systems used by [CONTACT_620800]/designee  will be secured  and password protected.  
CONFIDENTIAL    Protocol BNC210.012              Version 4.0 (US) , 17-Nov-2022 
 
 54 • The participant must be informed that his/her medical records may be examined by 
[CONTACT_78582], by [CONTACT_42506], and by [CONTACT_48011].  
10.1.5.  Independent Safety Review  
An independent Safety Review Committee will  be established to monitor participant  safety 
throughout the study. The meetings will occur approximately every 3 months and will review all 
safety data including vital signs, ECG, pathology results, physical examinations, C -SSRS and 
continuous AE reportin g. 
10.1.6.  Data Quality Assurance  
• All participant data relating to the study will be recorded in the e CRF unless transmitted 
to the Sponsor or designee electronically ( e.g., laboratory data). The Investigator is 
responsible for verifying that data entries are accurate and correct by [CONTACT_620801].  
• Guidance on completion of eCRFs will be provided in the study specific eCRF 
completion guidelines . 
• The Investigator must permit study -related monitoring, audits, IRB review, and 
regulatory agency inspections and provide direct access to source data documents.  
• Quality tolerance limits (QTLs) will be predefined in the study specific Risk Log  to 
identify system atic issues that can impact participant safety and/or reliability of study 
results. These predefined parameters will be monitored during the study, and important 
deviations from the QTLs and remedial actions taken will be summarized in the Clinical 
Study Report.  
• Monitoring details describing strategy , including definition of study critical data items 
and processes (e.g., risk -based initiatives in operations and quality such as risk 
management and mitigation strategies and analytical risk-based monitoring), methods, 
responsibilities , and requirements, including handling of noncompliance issues and 
monitoring techniques (central, remote, or on -site monitoring) are provided in the  
Clinical Monitoring Plan . 
• The Sponsor or designee is responsible for the data man agement of this study , including 
quality checking of the data.  
• The Sponsor assumes accountability for actions delegated to other individuals ( e.g., 
contract research organizations).  
• Records and documents, including signed ICFs, pertaining to the conduct of this study 
must be retained by [CONTACT_13177] 15 years after study completion unless local 
regulations or institutional policies require a longer retention period. No records may be 
destroyed during the retention period without the written approval of the Sponsor. No 
records may be transferred to another location or party without written notification to the 
Sponsor.  
CONFIDENTIAL    Protocol BNC210.012              Version 4.0 (US) , 17-Nov-2022 
 
 55 10.1.7.  Source Documents  
• Source documents provide evidence for the existence of the participant and substantiate 
the integrity of the data collected. Source documents are filed at the Investigator’s site.  
• Data ent ered in the eCRF that are transcribed from source documents must be consistent 
with the source documents , or the discrepancies must be explained. The Investigator may 
need to request previous medical records or transfer records, depending on the study. 
Also, current medical records must be available.  
• Examples of acceptable source documentation include, but are not limited to, hospi[INVESTIGATOR_2553], clinic and office charts, laboratory notes, and recorded data from automated 
instruments, memoranda, and pharmacy d ispensing records.  The Investigator must 
maintain accurate documentation (source data) that supports the information entered in 
the eCRF.  
• Study monitors will perform ongoing source data verification to confirm that data entered 
into the eCRF by [CONTACT_1191], complete, and verifiable from 
source documents; that the safety and rights of participants are being protected; and that 
the study is being conducted in accordance with the currently approved protocol and any 
other study agreem ents, ICH GCP, and all applicable regulatory requirements.  
10.1.8.  Study and Site Closure  
The Sponsor or designee reserves the right to close the study site or terminate the study at any 
time for any reason at the sole discretion of the Sponsor. Study sites will b e closed upon study 
completion. A study site is considered closed when all required documents and study supplies 
have been collected and a study -site closure visit has been performed.  
The Investigator may initiate study -site closure at any time, provided t here is reasonable cause 
and sufficient notice is given in advance of the intended termination.  
Reasons for the early closure of a study site by [CONTACT_9330]:  
For study termination:  
• Discontinuation of furth er study intervention development  
For site termination:  
• Failure of the Investigator to comply with the protocol, the requirements of the IRB or 
local health authorities, the Sponsor's procedures, or GCP guidelines  
• Inadequate  or no  recruitment  (evaluated after a reasonable amount of time)  of participants 
by [CONTACT_737]  
• Total number of participants included earlier than expected  
If the study is prematurely terminated or suspended, the Sponsor shall promptly inform the 
Investigators, the IRBs, the regulatory authorities, and any contract research organization(s) used 
in the s tudy of the reason for termination or suspension, as specified by [CONTACT_56859]. The Investigator shall promptly inform the participant  and should assure 
appropriate participant  therapy and/or follow -up. 
CONFIDENTIAL    Protocol BNC210.012              Version 4.0 (US) , 17-Nov-2022 
 
 56 10.1.9.  Publication Policy  
The publication policy is outlined in the study site specific Clinical Trial Agreement.  
 
  
CONFIDENTIAL    Protocol BNC210.012              Version 4.0 (US) , 17-Nov-2022 
 
 58 Pregnancy 
testing  • Highly sensitive serum  human chorionic gonadotropin (hCG) pregnancy 
test (as needed for women of childbearing potential)3 
Other 
Screening 
Tests  • Follicle -stimulating hormone and estradiol (as needed in women of 
non-childbearing potential only)  
• Serology (HIV antibody, hepatitis B surface antigen [HBsAg], and 
hepatitis C virus antibody)  
• All study -required laboratory tests will be performed by a central 
laboratory, with the exception of:  
o Urine drug test and pregnancy test at Baseline , Week 4, Week [ADDRESS_826249], ALP, and bilirubin (direct and total) at Week 6 and 
Week 10  
NOTES:  
1. Details of liver chemistry stoppi[INVESTIGATOR_21357] -up are given in 
Section 7.1.1 Liver Chemistry Stoppi[INVESTIGATOR_620773] 5: Liver Safety: Suggested 
Actions and Follow -up Assessments.  All events of ALT or AST 3 × upper limit of normal 
(ULN) and total bilirubin 2 × ULN (>35% direct bilirubin) which may indicate severe liver 
injury (possible Hy’s Law), must be reported to the Medical Monitor in an expedited manner 
(excluding studies of hepatic impairment or cirrhosis).  
2. If alkaline phosphatase is elevated, consider fractionating.  
3. Local urine testing will be standard for the protocol unless serum testing is required by [CONTACT_31857].  
 
Investigators must document their review of each laboratory safety report.  
  
CONFIDENTIAL    Protocol BNC210.012              Version 4.0 (US) , 17-Nov-2022 
 
 63 • The Investigator will also consult the Investigator’s Brochure and/or product 
information, for marketed products, in his/her assessment.  
• For each AE/SAE, the Investigator must  document in the medical notes that he/she has 
reviewed the AE/SAE and has provided an assessment of causality.  
• There may be situations in which an SAE has occurred and the Investigator has 
minimal information to include in the initial report to the Sponsor or designee . 
However, it is v ery important that the Investigator always make an assessment of 
causality for every event before the initial transmission of the SAE data to the Sponsor 
or designee . 
• The Investigator may change his/her opi[INVESTIGATOR_9242] -up 
informatio n and send a n SAE follow -up report with the updated causality assessment.  
The causality assessment is one of the criteria used when determining regulatory reporting 
requirements.  
The Investigator will use clinical judgment to determine the relationship  following the below 
definitions:  
• Not Related: This category applies to an AE that is clearly not related to the 
investigational agent/procedure, beyond a reasonable doubt. That is, another cause of 
the event is most plausible; an d/or a clinically plausible temporal sequence is 
inconsistent with the onset of the event and the administration of study intervention  
and/or a causal relationship is considered biologically implausible.  
 
• Unlikely Related: This category applies to an AE that could reasonably be considered 
caused by [CONTACT_6615], and where there is no known or expected response pattern to 
the suspected study intervention . 
 
• Possibly Related: This category applies to an AE that follows a reas onable temporal 
sequence from administration of the study intervention  and that follows a known or 
expected response pattern to the suspected study intervention , but that could readily 
have been produced by a number of other factors  
 
• Probably Related: This category applies to an AE that follows a reasonable temporal 
sequence from administration of the study intervention ; that follows a known response 
pattern to the suspected study intervention ; that is confirmed by [CONTACT_620802][INVESTIGATOR_620774] ; and that cannot be reasonably explained by [CONTACT_2416] ’s clinical state.  
• Definitely Related:  This category applies to an AE that is plausible, and concurrent 
disease or other drugs or chemicals cannot explain event. The response to withdrawal 
of the study intervention  (dechallenge) should be clinically plausible. The event must 
be definitive pharm acologically or phenomenologically, using a satisfactory 
rechallenge procedure if necessary.  
CONFIDENTIAL    Protocol BNC210.012              Version 4.0 (US) , 17-Nov-2022 
 
 65 • Date of occurrence of the event  
• Severity of  the SAE term 
• A brief description of the  event, treatment, outcome to date, and any actions taken  with 
study intervention  
• The seriousness criteria(on) that were met  
• Investigator causality assessment  
• Concomitant medication s being taken  within 30 days of  onset of the event  
• Relevant  medical history  information  
• Relevant  laboratory test findings  
• Whether and when the Investigator was unblinded as to the participant ’s treatment 
assignment  
Any missing or additional relevant follow -up information concerning the SAE should be sent 
to the  via the same contact [CONTACT_620803] a follow -up SAE Report Form, together with the followi ng minimal 
information ; initial report, adverse event, date of occurrence, study participant identifier , and 
site number . This will allow the follow -up information to be linked to the initial SAE report.  
Specific information may be requested by [CONTACT_620804] a follow -up request form or via email communication.  
The Investigator is required to comply with applicable regulations (including local laws and 
guidances) regarding the notification of his or her health autho rities, IRB, Principal and 
Coordinating Investigators, Study Investigators, and institutions. Each Investigator is obligated 
to learn about the reporting requirements for Investigators in his/her country. The study 
monitor may be able to assist with this.  
 
  

CONFIDENTIAL    Protocol BNC210.012              Version 4.0 (US) , 17-Nov-2022 
 
 66 10.4. Appendix 4: Contraceptive and Barrier Guidance  
10.4.1.  Definitions  
Woman of Childbearing Potential (WOCBP)  
Women in the following categories are considered WOCBP (fertile):  
1. Following menarche  
2. From the time of menarche until becoming pos tmenopausal unless permanently sterile 
(see below)  
• A postmenopausal state is defined as no menses for 12 months without an alternative 
medical cause.  
o A high follicle -stimulating hormone (FSH) level in the postmenopausal range may be 
used to confirm a postmenopausal state in women not using hormonal contraception 
or hormonal replacement therapy (HRT). However, in the absence of [ADDRESS_826250] discontinue HRT to allow 
confirmation of postmenopausal status before study enrollment.  
• Permanent sterilization methods (for the purpose of this study) include:  
o Documented hysterect omy 
o Documented bilateral salpi[INVESTIGATOR_1656]  
o Documented bilateral oophorectomy  
o For individuals with permanent infertility due to an alternate medical cause other than 
the above,  (e.g., Mullerian agenesis, androgen insensitivity, gonadal dysgenesis), 
investigator discretion should be applied to determining study entry.  
Note:  Documentation can come from the site personnel’s review of the participant’s medical 
records, medical examination, or medical history interview.  
• If fertility is unclear ( e.g., amen orrhea in adolescents or athletes) and a menstrual cycle 
cannot be confirmed before first dose of study intervention, additional evaluation should 
be considered.  
 
 
 
 
 
CONFIDENTIAL    Protocol BNC210.012              Version 4.0 (US) , 17-Nov-2022 
 
 67 10.4.2.  Contraception Guidance  
CONTRACEPTIVESa ALLOWED DURING THE STUDY INCLUDE:  
Highly Effective Methodsb That Have Low User Dependency  
• Implantable progestogen -only hormone contraception associated with inhibition of ovulationc 
• Intrauterine device (IUD)  
• Intrauterine hormone -releasing system (IUS)c 
• Bilateral tubal occlusion  
• Azoospermic partner (vasectomized or due to a medical cause)  
Azoospermia is a highly effective contraceptive method provided that the partner is the sole sexual partner of 
the woman of childbearing potential and the absence of sperm has been confirmed. If not, an additional highly 
effective method of contraception should be used. Spermatogenesis cycle is approximately 90 days.  
Note: docu mentation of azoospermia for a male participant can come from the site personnel’s review of the 
participant’s medical records, medical examination, or medical history interview.  
Highly Effective Methodsb That Are User Dependent  
• Combined (estrogen - and progestogen -containing) hormonal contraception associated with inhibition of 
ovulationc 
o oral 
o intravaginal  
o transdermal  
o injectable  
• Progestogen -only hormone contraception associated with inhibition of ovulationc 
o oral 
o injectable  
• Sexual abstinence  
Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual 
intercourse during the entire period of risk associated with the study intervention. The reliability of sexual 
abstinence needs to be evalu ated in relation to the duration of the study and the preferred and usual lifestyle of the 
participant.  
a) Contraceptive use by [CONTACT_103092].  
b) Failure rate of <  1% per year when used consistently and correctly.  Typi[INVESTIGATOR_17964].  
c) Male condoms must be used in addition to hormonal contraception.  If locally requir ed, in accordance with 
Clinical Trial Facilitation Group (CTFG) guidelines, acceptable contraceptive methods are limited to those 
which inhibit ovulation as the primary mode of action.  
Note: Periodic abstinence (calendar, symptothermal, postovulation meth ods), withdrawal (coitus interruptus), 
spermicides only, and lactational amenorrhea method (LAM) are not acceptable methods of contraception for this 
study.  Male condom and female condom should not be used together (due to risk of failure from friction).  
  
CONFIDENTIAL    Protocol BNC210.012              Version 4.0 (US) , 17-Nov-2022 
 
 68 10.5. Appendix 5: Liver Safety: Suggested Actions and Follow -up 
Assessments  
Phase [ADDRESS_826251]  [ADDRESS_826252]  [ADDRESS_826253] persists for  [ADDRESS_826254]  [ADDRESS_826255] and total bilirubin  [ADDRESS_826256] (>  35% 
direct bilirubin)  
INR2 ALT or AST  [ADDRESS_826257] and international normalized ratio (INR) 
> 1.[ADDRESS_826258]   [ADDRESS_826259]  [ADDRESS_826260] associated with symptoms (new or 
worsening) believed to be related to liver injury or hypersensitivity  
Suggested Actions, Monitoring, and Follow -up Assessments  
Actions  Follow -Up Assessments  
• Immediately discontinue study 
intervention.  
• Report the event to the Medical Monitor 
within 24 hours.  
• Complete a Serious Adverse Event Report 
Form if the event  also met the criteria for 
an SAE.2 
• Perform follow -up assessments as 
described in the Follow Up Assessment 
column.  
• Monitor the participant until liver 
chemistry test abnormalities r esolve, 
stabilize, or return to baseline.  
MONITORING:  
If ALT or AST  [ADDRESS_826261] AND total 
bilirubin  [ADDRESS_826262] or INR >  1.5:  • Viral hepatitis serology4 
• Obtain serum creatine phosphokinase 
(CPK), lactate dehydrogenase (LDH), 
gamma -glutamyltransferase [GGT], 
glutamate dehydrogenase [GLDH], and 
serum albumin.  
• Fractionate bilirubin, if total bilirubin 
 [ADDRESS_826263].  
• Obtain complete blood count with 
differential to assess eosinophilia.  
• Record the appearance or worsening of 
clinical symptoms of liver injury, or 
hypersensitivity.  
• Record use of concomitant medications 
(including acetaminophen, herbal 
remedies, and ot her over -the-counter 
CONFIDENTIAL    Protocol BNC210.012              Version 4.0 (US) , 17-Nov-2022 
 
 69 • Repeat liver chemistry tests (include ALT, 
AST, ALP, total bilirubin, and INR) and 
perform liver event follow up assessments 
within 24 hours.  
• Monitor participant twice weekly until 
liver chemistry test abnormalities resolve, 
stabilize, or return to baseline.  
• A hepatology consultation is 
recommended.  
If ALT or AST   [ADDRESS_826264] AND total 
bilirubin <  [ADDRESS_826265] and INR  1.5:  
• Repeat liver chemistry tests (include ALT, 
AST, alkaline phosphatase, total bilirubin, 
and INR) and perform liver chemistry 
follow -up assessments within 24 to 72 
hours.  
• Monitor participants weekly until liver 
chemistry abnormalities resolve, stabilize, 
or return to baseline.  
 
 
• Do not restart/rechallenge  participant 
with study intervention . 
 medications) on the concomitant 
medications eCRF.  
• Record alcohol use  
If ALT or AST   [ADDRESS_826266] AND total 
bilirubin  [ADDRESS_826267] or INR >  1.5 obtain the 
following in addition to the assessments listed 
above : 
• Antinuclear antibody, antismooth muscle 
antibody, Type 1 antiliver kidney 
microsomal antibodies, and quantitative 
total immunoglobulin G (IgG), or gamma 
globulins  
• Liver imaging (ultrasound, magnetic 
resonance, or computerized tomography) 
to evaluate liver disease  
• Liver biopsy m ay be considered and 
discussed with local specialist if available, 
for instance:  
o In participants when serology raises 
the possibility of autoimmune hepatitis 
(AIH)  
o In participants when suspected drug 
induced liver injury (DILI) progresses 
or fails to resol ve on withdrawal of 
study intervention  
o In participants with acute or chronic 
atypi[INVESTIGATOR_31790]  
• Report all assessments conducted to 
the Medical Monitor as they become 
available  
1. Serum bilirubin fractionation should be performed if testing is available. If serum bilirubin fractionation testing is unavai lable, 
record the absence/presence of detectable urinary bilirubin on dipstick  which is indicative of direct bilirubin elevations 
suggesting liver injury.  
2. All events of ALT or AST > [ADDRESS_826268] and total bilirubin > [ADDRESS_826269] (> 35% direct bilirubin) or ALT or AST > [ADDRESS_826270] and 
INR > 1.5 may indicate severe liver injury (possible ‘Hy’s Law’) and must be reported to sponsor in an expedited manner 
and as an SAE if SAE criteria met (excluding studies of hepatic impairment or cirrhosis).  The INR stated threshold value 
will not apply to participants receiving anticoagulants.  
CONFIDENTIAL    Protocol BNC210.012              Version 4.0 (US) , 17-Nov-2022 
 
 70 3. New or worsening symptoms believed to be related to liver injury (such  as fatigue, nausea, vomiting, right upper quadrant pain 
or tenderness, or jaundice) or hypersensitivity (such as fever, rash, or eosinophilia).  
4. Includes: Hepatitis A immunoglobulin M (IgM) antibody; HBsAg and HBcAb; hepatitis C RNA; cytomegalovirus IgM 
antibody; Epstein -Barr viral capsid antigen IgM antibody (or if unavailable, heterophile antibody or monospot testing); and 
hepatitis E IgM antibody.  
 
CONFIDENTIAL    Protocol BNC210.012              Version 4.0 (US) , 17-Nov-2022 
 
 71 10.6. Appendix 6: Abbreviations  
Abbreviation  Definition  
AE Adverse Event  
ACC  Anterior Cingulate Cortex  
ADL  Activities of Daily Living  
ALP  Alkaline Phosphatase  
ALT  Alanine Transaminase  
AST  Aspartate Transaminase  
AUC 90 Exposure at 90% of maximal effect  
b.i.d. Twice Daily 
BUN  Blood Urea Nitrogen  
C-SSRS  Columbia Suicide Severity Rating Scale  
CAPS -5 Clinician -Administered PTSD Scale for the DSM -5 
CGI-I Clinical Global Impressions – Improvement  
CGI-S Clinical Global Impressions – Severity  
CNS  Central Nervous System  
COVID -19 Coronavirus disease 2019  
DSM -5 Diagnostic and Statistical Manual of Mental Disorders, 5th 
Edition  
ECG  Electrocardiogram  
eCRF  Electronic Case Report Form  
fMRI  Functional Magnetic Resonance Imaging  
FSH Follicle Stimulating Hormone  
GAD  Generalized Anxiety Disorder  
GCP  Good Clinical Practice  
GLP  Good Laboratory Practice  
HAM -A Hamilton Anxiety Rating Scale 
HBsAg Hepatitis B Surface Antigen  
HCV  Hepatitis C Virus 
HIV Human Immunodeficiency Virus 
HRT  Hormone Replacement Therapy  
 
CONFIDENTIAL    Protocol BNC210.012              Version 4.0 (US) , 17-Nov-[ADDRESS_826271] for DSM -5 
PEER  Pre-Enrollment Eligibility Review  
PGI-I Patient  Global Impressions – Improvement  
PGI-S Patient  Global Impressions – Severity  
PK Pharmacokinetic  
PP Per Protocol  
PRO  Patient Reported Outcome  
PT Preferred Term  
PTSD  Post-Traumatic Stress Disorder  
QTcF  Fridericia -corrected QT Interval  
QTL  Quality Tolerance Limit  
SAE  Serious Adverse Event  
SAP Statistical Analysis Plan  
SCID -5-CT Structured Clinical Interview for DSM -5 Disorder s – 
Clinical Trials Version  
SCID-5-PD Structured Clinical Interview for DSM -5 Disorders – 
Personality Disorders  
SD Standard Deviation  
CONFIDENTIAL    Protocol BNC210.012              Version 4.0 (US) , 17-Nov-[ADDRESS_826272]  Upper Limit of Normal  
WOCBP  Women of Child Bearing Potential  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CONFIDENTIAL    Protocol BNC210.012              Version 4.0 (US) , 17-Nov-[ADDRESS_826273] -traumatic Stress Disorder. In: Combat Veterans  Focus 
Pharmacy &Therapeutics. 2012 ; 371:32 -8. 
Clinician Administered PT SD Scale for DSM -5 (CAPS -5). Accessed at  
http://www.ptsd.va.gov/professional/assessment/adult -int/caps.asp  
PTSD Checklist for DSM -5 (PCL -5). Accessed at 
https://www.ptsd.va.gov/professional/assessment/adult -sr/ptsd -checklist.asp  
Hamilton M. The assessment of anxiety states by [CONTACT_35254]. Br. J. Med. Psychol. 1959 ; 32:50 –55. 
Krystal JH, Davis LL, Neylan TC, A Raskind M, Schnurr PP, Stein MB, et al. It Is Time to 
Address the Crisis in the Pharmacotherapy of Posttraumatic Stress Disorder: A Consensus 
Statement of the PTSD Psychopharmacology Working Group. Biol Psychiatry. 2017;  82(7):e51 -
e59. 
Morin CM.   Insomnia:   Psychological assessment and management. Guilford Press, [LOCATION_001].  
1993.  
Veterans Affairs /Department of Defense  Clinical Practice Guideline for the Management of 
Posttraumatic Stress Disorder and  Acute Stress Disorder Prepared by: [CONTACT_620805] G roup with Support From: The Office of Quality, Safety 
and Value, VA, Washington, DC & Office of Evidence Based Practice, U.S. Army Medical 
Command Version 3.0 – 2017 based On  Evidence Reviewed Through March 2016. Accessed at:  
https://www.healthquality.va.g ov/guidelines/MH/ptsd/VADoDPTSDCPGFinal012418.pdf  
Williams, J. B. and K. A. Kobak. Development and reliability of a structured interview guide for 
the Montgomery Åsberg Depression Rating Scale (SIGMA). Br.  J. Psychiatry. 2008. 192.1:52 -
58. 
 
 
 